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Autophagy is a physiological, conserved catabolic process by which cytoplasmic 
material is delivered for degradation into lysosomes. Autophagy plays a role in several 
cellular processes and in various aspects of immunity but its role in trafficking 
pathways and major histocompatibility complex (MHC) class I presentation has only 
been poorly described. Here, we show that molecular machinery of autophagy 
regulates MHC class I surface levels and intracellular antigen presentation in vitro and 
in vivo. Briefly, it has been found that MHC class I molecules are stabilized on the cell 
surface of murine antigen presenting cells deficient for core components of autophagy, 
such as ATG5 or ATG7. This stabilization seems to result from defective internalization 
of MHC class I molecules dependent on adaptor protein kinase 1 (AAK1), a member of 
clathrin-dependent endocytosis machinery. Indeed, AAK1 interacts with the cytosolic 
form of LC3 (Microtubule-associated protein 1A/1B-light chain 3), a pivotal molecule 
of autophagy, and it is recruited to the MHC class I internalization machinery upon LC3 
lipidation. Therefore, when autophagy and specifically, LC3 lipidation is blocked, MHC 
class I molecules get stabilized on the surface of dendritic cells resulting in a more 
efficient stimulation of CD8+ T cell responses in vitro and in vivo. Importantly, the 
absence of autophagy-dependent internalization during viral infections, such as 
influenza virus and lymphocytic choriomeningitis virus, leads to enhance virus-specific 
CD8+T cell responses in vivo and a better immune control of influenza infection. 
Additionally, preliminary studies using B cells infected by Epstein Barr virus  and 
deficient for the transporter-associated with antigen presentation (TAP), a key protein 
in the MHC class I presentation pathway, suggest a contribution of autophagy in the 
regulation of intracellular MHC class I antigen presentation. Indeed, preliminary data 
show that autophagy might contribute to deliver antigens as well as to supply MHC 
class I molecules to an endosomal compartment for an alternative MHC class I antigen 
processing and presentation as a consequence of the impairment of classical MHC class 
I antigen processing. These findings clearly show that the autophagy machinery 
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orchestrates T cell immunity by regulating MHC class I surface expression levels and it 
can also help to improve adaptive immune response against viral pathogens by 
circumventing viral immune escape mechanisms. 
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Autophagie ist ein physiologischer, konservierter und katabolischer Prozess, durch 
den zytoplasmatisches Material zum Abbau in Lysosomen transportiert wird. 
Autophagy spielt eine Rolle in mehreren zellulären Prozessen und in verschiedenen 
Aspekten der Immunität, aber seine Rolle im Membrantransport und der 
Antigenpräsentation durch Major Histokompatibilität Komplex (MHC) Klasse I 
Moleküle wurde bisher nur ansatzweise beschrieben. Hier zeigen wir, dass die 
molekulare Maschinerie der Autophagie die Oberflächenexpression von MHC-Klasse-I-
Molekülen und die intrazelluläre Antigenpräsentation in vitro und in vivo reguliert. 
Zusammenfassend wurde durch unsere Studien bestimmt, dass MHC-Klasse-I-
Moleküle auf der Zelloberfläche von murinen Antigen-präsentierenden Zellen, die für 
Kernkomponenten der Autophagie, wie ATG5 oder ATG7, defizient sind, stabilisiert 
wird. Diese Stabilisierung resultiert aus einer defekten Internalisierung von MHC-
Klasse-I-Molekülen, abhängig von der Adapterprotein-Kinase 1 (AAK1), einem Mitglied 
der Clathrin-abhängigen Endozytose-Maschinerie. In der Tat interagiert AAK1 mit der 
zytosolischen Form von LC3 (Microtubuli-assoziiertes Protein 1A / 1B-leichte Kette 3), 
einem zentrales Molekül der Autophagie, und diese Kinase wird zur MHC-Klasse-I-
Internalisierungsmaschine bei LC3-Lipidierung rekrutiert. Daher werden, wenn 
Autophagie und insbesondere LC3-Lipidierung blockiert sind, MHC-Klasse-I-Moleküle 
auf der Oberfläche der dendritischen Zellen stabilisiert, was zu einer effizienteren 
Stimulation von CD8+ T-Zellen in vitro und in vivo führt. Wichtig ist, dass das Fehlen 
einer autophagieabhängigen Internalisierung bei Virusinfektionen, wie durch den 
Influenzavirus und den lymphozytischen Choriomeningitisvirus, dazu führt, dass 
Virus-spezifische CD8+ T-Zellreaktionen und eine bessere Immunkontrolle der 
Influenza-Infektion in vivo verstärkt werden. Darüber hinaus weisen vorläufige 
Studien mit B-Zellen, die durch das Epstein-Barr-Virus infiziert wurden und für den 
mit der Antigenpräsentation assoziierten Transporter (TAP), ein Schlüsselprotein im 
MHC-Klasse-I-Antigenpräsentationsweg, defizient sind, auf einen Beitrag der 
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Autophagie bei der Regulation der intrazellulären MHC-Klasse I vermittelten 
Antigenpräsentation hin. Tatsächlich zeigen vorläufige Daten, dass Autophagie dazu 
beitragen kann, Antigene für einen TAP unabhängigen MHC-Klasse I-
Antigenpräsentationsweg zu liefern, sowie MHC-Klasse-I-Moleküle zu einem 
endosomales Kompartiment für eine alternative MHC-Klasse-I-Antigenpräsentation zu 
transportieren. Diese Ergebnisse zeigen deutlich, dass die Autophagie-Maschinerie die 
T-Zell-Immunität durch Regulierung der MHC-Klasse-I-Oberflächenexpression 
orchestriert und sie auch dazu beitragen kann, die adaptive Immunantwort gegen 
virale Pathogene zu verbessern, indem virale Immunabwehrmechanismen, wie TAP 
Inhibition, umgangen werden. 
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1.1.1 Principles and biological role of antigen presentation  
Antigen presentation is a term used to describe a non-selective process of the immune 
system by which self and foreign material is presented by the cell to the specialized arm of the 
immune defences specifically to B and T cells, to induce highly specific mechanism to fight off 
the presented entity. Despite that such a process can be accomplished by all cells, three types of 
immune cells (macrophages, dendritic cells (DCs), and B cells) are categorized as professional 
antigen presenting cells. The antigen, any molecule able to trigger an immune response, can 
belong to either host or host-external components such as pathogens and it can be parts of 
proteins (peptides), lipids or sugars (polysaccharides). Physiologically, T cells against host 
antigens are negatively selected in the thymus and removed to ensure the host does not attack 
its own components. As peptide, antigen is presented at the surface of antigen presenting cells 
on molecules called Major Histocompatibility Complex (MHC) or human leukocyte antigen 
(HLA) molecules. Interestingly, T cells are able to recognize only some antigens and only if they 
are presented in the context of MHC molecules, phenomena known as peptide 
immunodominance and MHC restriction, respectively (Doherty and Zinkernagel 1975; Akram 
and Inman 2012). Moreover, different subclasses of T cells are activated based on which MHC 
complex presents the antigen. Classically, endogenous, cytosolic antigens are loaded on MHC 
class I molecules (MHC-I) and recognized by CD8+ (cytotoxic) T lymphocytes. In contrast, 
exogenous, extracellular, antigens, taken up by endocytosis or phagocytosis, are then loaded on 
MHC class II molecules (MHC-II) and presented to CD4+ T (helper) cells. However, there are 
exceptions to this distinction. Indeed, MHC-I molecules can present extracellular, endocytosed 
antigen in a process called cross-presentation, primarily by specialized antigen presenting cells, 
and similarly, peptides of intracellular origin can be loaded onto MHC-II molecules. The 
mechanism of antigen presentation has a central physiological role as it is responsible for the 
distinction between self/non-self-specific T cells and the consequent specific immune response 
to pathogen or to self-proteins causing autoimmune disorders. Moreover, it is the basis of 
vaccine development. In the following sections, biology of MHC-I molecules, MHC-I antigen 
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presentation pathways, and MHC-I trafficking will be presented. Finally, the role of MHC-I 
presentation as mechanism to provide immunological control against three viral infections will 
be described. 
1.1.2 MHC class I biology and MHC class I polymorphism 
MHC-I molecules are glycoproteins, members of the immunoglobulin superfamily displayed 
on the cell surface of all nucleated cells. They are heterodimers comprising a heavy chain and 
β2-microglobulin. Their structure is shown in Figure 1.1. 
 
Figure 1.1 MHC class I structure 
MHC-I molecules are heterodimers formed by the heavy chain α and β2-microglobulin. The heavy chain has 
three extracellular domains (α1, α2 and α3), a transmembrane section and a short cytoplasmic tail. The α1 and α2 
domains create the antigen binding cleft. 3 and 2-microglobulin are Ig domains. Figure adapted from what-when-
how.com  
The MHC-I heavy chain locus comprises a group of different genes, which are expressed 
simultaneously by all cells. In humans, it encodes “classical MHC-I” (HLA-A, HLA-B and HLA-C) 
and “non-classical MHC-I” (HLA-E, HLA-F and HLA-G, Hfe, MHC-I polypeptide-related sequence A 
(MICA) and MHC-I polypeptide-related sequence B (MICB)). Similarly, in mice, the MHC-I locus, 
called also H2, encodes for H-2D, H-2K, and H-2L (classical) and H-2Q, H-2M and H-2T (non-
classical). The non-classical MHC-I molecules are structurally highly related to the classical ones 
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and an increasing overlap of features with classical MHC-I has been observed (Kumanovics, 
Takada et al. 2003).  
The ability of MHC-I molecules to bind a broad range of antigens, called antigen repertoire, is 
given by the high level of polymorphisms within the heavy chain. An elaborate nomenclature 
system, shown in Figure 1.2, has been developed to distinguish all the different alleles.  
 
Figure 1.2 MHC-I nomenclature  
Synonymous DNA mutation indicates a nucleotide change within the DNA sequence, which does not influence the 
protein sequence. Exon and intron indicate the coding and non-coding region of the DNA, respectively. The last field, the 
level of expression can be N, null allele; L, low expression; S, secreted form; A, aberrant expression; and Q, questionable. 
1.1.3 Antigen processing and MHC-I presentation pathways 
As mentioned, MHC-I molecules can present both endogenous and exogenous antigens by 
classical and cross-presentation pathway, respectively. 
In the classical MHC-I pathway, the formation of peptide-MHC-I complex is the result of a 
highly regulated cascade of events that starts with antigen processing (Figure 1.3). Cytosol-
derived proteins, mainly incomplete or misfolded proteins named DRiPs, for Defective Ribosomal 
Products (Yewdell, Anton et al. 1996) are processed by the proteasome, a complex multisubunit 
proteolytic system in the cytosol. Proteins addressed to be degraded by the proteasome are 
marked by the addition of a chain of a small regulatory proteins called ubiquitin, to a lysine 
residue within the protein or its N-terminus. The proteasome-generated peptides range from 3 to 
22 amino acids in length and among them only 15% are products of 8-9 residues available for 
being used for MHC-I presentation (Kisselev, Akopian et al. 1999). Interestingly, some peptides 
can derive from non-contiguous sequences in the original protein by splicing events mediated by 
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the proteasome (Liepe, Marino et al. 2016). Peptides are then translocated into the endoplasmic 
reticulum (ER) lumen by the transporter associated with antigen processing (TAP) in an ATP-
dependant manner (van Endert, Saveanu et al. 2002). However, longer peptides may also be 
transported (Uebel and Tampe 1999). These peptides require additional N-terminal trimming in 
the ER before binding to MHC-I molecules by the ER aminopeptidase 1 (ERAP1 or ERAAP in 
mouse). In the ER, calnexin and ERp57 drive the formation of the MHC-I heterodimers, which 
subsequently associate with the peptide loading complex (PLC), which comprises TAP, tapasin, 
calreticulin, and ERp57. PLC stabilizes unloaded MHC-I molecules and facilitates peptide 
binding to MHC-I molecules (Figure 1.3).  
 
Figure 1.3 MHC class I pathway. 
New synthetized, empty MHC-I molecules enter the ER immediately after their translation and they get 
assembled by calnexin (CNX) and stabilized by the peptide loading complex (PLC) that contains calreticulin 
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(CRT), ERp57, tapasin (TPN), and the transporter associated with antigen presentation (TAP). Ubiquitinated 
(Ub) cytosolic proteins are degraded by the proteasome and the resulting peptides are translocated into the 
ER via TAP, eventually subjected to further trimming by the ER-associated aminopeptidase (ERAAP), and 
then loaded into the MHC-I. Once loaded the complex peptide-MHC-I is then transported to the Golgi through 
the ER-Golgi intermediate compartment (ERGIC) and reaches the cell surface. Unstable MHC-I molecules are 
translocated back to the cytosol by retrograde translocation and degraded by the proteasome in a process 
called ER-associated degradation (ERAD). 
If the peptide affinity is high, the MHC-I molecule dissociates from the PLC and can be 
transported from the ER to the ER-Golgi intermediate compartment (ERGIC) and then via the 
Golgi apparatus to the cell surface (Barlowe and Miller 2013). On the other hand, unstable MHC-
I molecules are destroyed in the cytosol by the proteasome by a process called ER-associated 
degradation (Ahner and Brodsky 2004). 
However, when the above-described MHC-I classical pathway is impaired, for example because 
of manipulation by pathogens or deficiency of cells for some components of the classical MHC-I 
pathway, alternative pathways exist to ensure MHC-I-restricted antigen presentation. The 
existence of alternative pathways for MHC-I antigen presentation has emerged from studies on 
cells with proteasome and TAP deficiencies. Indeed, individuals affected by bare lymphocyte 
syndrome-I, linked to TAP-deficiency, present a polyclonal repertoire of CD8+ T cells and do not 
succumb to viral infections, supporting the hypothesis of alternative presentation pathways (de la 
Salle, Houssaint et al. 1997). Immunogenic peptides produced from alternative TAP-independent 
routes are named “T cell epitopes associated with impaired peptide processing” (TEIPP). The 
loading mechanism of TEIPP into MHC-I molecules is incompletely known. By studying latent 
membrane protein 2 (LMP2) of Epstein Barr virus (EBV), it has been suggested that after 
proteasome proteolysis, some peptides can access the ER thanks to their hydrophobicity 
overcoming the lack of the peptide transporter TAP (Lautscham, Mayrhofer et al. 2001). 
Additionally, several studies have suggested that the catabolic process of autophagy can play a role 
as an alternative pathway for MHC-I presentation, especially in absence of TAP (See 1.2.6). The 
autophagy pathway will be introduced in the second part of the introduction, because the role of 
autophagy as alternative pathway in MHC-I-restricted antigen presentation is the main subject of 
the present PhD thesis. 
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MHC-I can also present peptides generated from exogenous proteins by cross-presentation. 
Three different pathways of cross-presentation have been identified so far. They are described 
in Figure 1.4. Upon internalization, proteins are degraded either by the proteasome in the 
cytosol or by proteases within phagosomes. Proteasome-produced peptides can then enter two 
ways: they can enter the classical MHC-I pathway via the ER where they are loaded on MHC-I 
(cytosolic pathway) or they are transported back into specialized compartments that have 
acquired ER-resident proteins after fusion with the ERGIC (ER-phagosome pathway). 
Differently, in a third pathway (vacuolar pathway) proteins are degraded and loaded within 
phagosomes onto MHC-I molecules of still unknown origin. It is indeed, under intense 
investigation whether the MHC-I molecules used in the vacuolar pathway are newly synthetized 
ones, coming from the ER, or are recycled from the plasma membrane. 
 
Figure 1.4 Cross-presentation pathways.  
Three pathways for cross-presentation have been described. Once internalized, the protein is 
transported from the phagosome to the cytosol, degraded by the proteasome and loaded on MHC-I 
molecules either in the ER (1, The phagosome to cytosolic pathway) or in a compartment derived from the 
fusion of phagosomes with components of the ER, such as TAP (2, ER-phagosome pathway). (3) The vacuolar 
pathway: Antigens can be directly processed in the phagosome and the resulting peptides are loaded onto 
MHC-I. 
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1.1.4 MHC class I internalization and organization of endocytic pathway 
Once at the plasma membrane, MHC-I are continuously removed by endocytosis and recycled 
back. Constitutive endocytosis of MHC-I molecules has been described for the first time almost 30 
years ago in B and T lymphocytes and in non-lymphoid (i.e. fibroblast) cells, as a process requiring 
the MHC-I cytoplasmic tail (Capps, Van Kampen et al. 1989; Vega and Strominger 1989). Since 
kinetics of internalization, recycling, and the intracellular localization vary according to the cell 
type, MHC-I trafficking is still under intense debate. Nevertheless, MHC-I have been described to 
follow different pathways in professional and nonprofessional APCs: clathrin-dependent and 
clathrin-independent endocytosis, respectively. During clathrin-dependent endocytosis, cargoes 
carrying a specific tyrosine-based recognition motif in their cytoplasmic tail are specifically 
recognized by adaptor molecules (Bonifacino and Dell'Angelica 1999). Among them, the adaptor 
protein 2 (AP-2) is responsible for cargo selection and, upon phosphorylation by adaptor-
associated kinase (AAK1), its affinity for the tyrosine motif within the target molecule increases 
(Honing, Ricotta et al. 2005) resulting in the invagination of the plasma membrane and formation 
of clathrin-coated vesicles. Such vesicles detach from the plasma membrane by the action of the 
GTPase dynamin and they fuse with early endosome upon clathrin removal by the heat shock 
cognate protein HSC70 and auxilin (Barouch, Prasad et al. 1997). The key role of the cryptic 
tyrosine motif within the cytoplasmic tail of MHC-I to drive their trafficking within the cells has 
been described in the context of cross-presentation in murine and human antigen-presenting cells  
(Lizee, Basha et al. 2003; Kulpa, Del Cid et al. 2013). Indeed, it has been shown that the tyrosine 
motif recognized also by the adaptor protein AP-1 is important for the trafficking of MHC-I 
molecules from the trans Golgi to a endolysosomal compartment important for cross-presentation 
of soluble antigens in antigen-presenting cells (Kulpa, Del Cid et al. 2013). In line, murine DCs 
lacking the cytosolic tyrosine motif have an impairment in cross-presentation with a subsequent 
negative impact on CD8+T cell response against two viral antigens (Lizee, Basha et al. 2003). Some 
years after the same group showed that this was due to a slower internalization of MHC-I 
molecules from the surface when the tyrosine motif was deleted, impeding the MHC-I to reach the 
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endolysosomal compartment devote to cross-presentation (Basha, Lizee et al. 2008). On the other 
hand, clathrin-independent endocytosis is a less characterized process and allows the endocytosis 
and recycling of plasma membrane molecules that lack the tyrosine motif for the clathrin-
dependent pathway. Clathrin-independent endocytosis consists of several pathways, and among 
them, it has been shown that ADP ribosyl factor 6 (Arf6)-dependent endocytosis plays a role in 
MHC-I internalization in HeLa and COS cells (Naslavsky, Weigert et al. 2004). As all GTPases, Arf6 
cycles from an active state (GTP-bound form), mediate by guanine nucleotide exchange factors 
(GEFs) to an inactive state (GDP-bound form) upon hydrolysis of GTP to GDP by GTPase activating 
proteins (GAPs).  The Arf6 cycle is important for its role in endosomal trafficking and actin 
remodelling (D'Souza-Schorey and Chavrier 2006). In non-professional antigen-presenting cells, 
MHC-I have been shown to be internalized by Arf6-dependent mechanism. Upon internalization, 
cargo-containing vesicles fuse with early endosome positive for the early endosomal marker, EEA-
1, encountering the clathrin-mediated pathway. Next steps of the MHC-I trafficking require 
another small GTPase, Rab22a (Cebrian, Croce et al. 2016). 
Upon internalization, MHC-I molecules, as any other molecule, enter the endocytic pathway, a 
dynamic cytosolic system of membrane compartments. Vesicles arising from different endocytosis 
pathways fuse with early endosomes, which are also called sorting endosomes due to their role as 
sorting station of the endocytic pathway (Figure 1.5). Indeed, from early endosomes, some 
receptors can recycle back to the cell surface in few minutes; some others are transported to the 
trans Golgi network entering a retrograde pathway; some, mainly ubiquitinated cargoes are 
usually delivered to late endosomes, multi-vesicular bodies (MVBs), and lysosomes for 
degradation; and finally, some proteins are sorted to the endosomal recycling compartment (ERC), 
a tubular structure which mediates a “slow” recycling.  
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Figure 1.5 Endocytic pathways. 
Proteins that are internalized through either clathrin-dependent or –independent pathways (CDE and CIE, 
respectively) are shuttled into early endosomes (EE) marked by the presence of RAB4, and RAB5. EEs regulate the 
sorting of the internalized cargoes. Some are rapidly or slowly recycled back to the plasma membrane in RAB35+ 
recycling endosomes (RE) or passing through the RAB11+ endosomal recycling compartment (ERC), respectively. 
Alternatively, mainly for endocytosed ubiquitinated proteins, EEs mature into multivesicular bodies (MVB) (CD63 and 
LAMP1+), late endosomes (LE) (RAB7) and finally fuse with lysosome identified as LAMP1 and 2+ compartments 
responsible for degradation. Pink hexagons represent the proteins at the membrane of the different compartments. 
Membrane compartments along the endocytic pathway are, in part, identified by composition of 
membrane markers such as Rab GTPase (Figure 1.5). Rab proteins recruit effector proteins, such 
as cargo adaptors, motor proteins to move the vesicles to its target membrane, as well as tethering 
complexes responsible for vesicles fusion by helping Soluble NSF Attachment Receptors 
(SNARE)(Hutagalung and Novick 2011).  
To note, even though compartment within the endosomal network have their identity, they are 
not stable entities as they are dynamic structure and they can be altered when molecules and 
cargoes are exchanged in a process called endosomal maturation. During maturation, protein 
composition of early endosomes changes and various hydrolases are recruited as a result of 
vacuolar acidification. As early endosomes mature to become late endosomes/MVBs, they can 
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accumulate intraluminal vesicles in their vacuole to which cargo is transported by a multi subunit 
endosomal-sorting complex. When an endosome fuse with a lysosome, the intraluminal vesicles in 
the resulting endolysosome are degraded by lysosomal hydrolases. Finally, the classical lysosome 
is formed (Pryor and Luzio 2009). 
1.1.5 Role of MHC class I antigen presentation for the immune control of 
influenza, LCMV and EBV 
Influenza viruses are enveloped RNA viruses that belong to the Orthomyxoviridae family 
(Hampson and Mackenzie 2006). They are categorized based on the combination of 
haemagglutinin, responsible for the tropism of the virus, and neuraminidase glycoproteins. The 
knowledge that we have on the development of influenza A virus (IAV) infection in vivo, derived 
mainly from studies on mice which are confirmed by few studies in humans (Sridhar, Begom et al. 
2013; Wang, Wan et al. 2015). It is clear that influenza-specific CD8+T cells, activated upon 
peptide-MHC-I complex recognition, have an important role in fighting the virus resulting in a 
complete elimination of IAV by day 9 post infection (Bender, Croghan et al. 1992; Doherty, Topham 
et al. 1996). The presentation of IAV antigens starts at day 1-2 in the lung lymph nodes, leading to 
the activation of IAV-specific CD8+ T cells (Yoon, Legge et al. 2007). The peak of antigen 
presentation within the lymph node is thought to occur from day 3 until at least day 9 post 
infection (Belz, Smith et al. 2004) but IAV-peptide-MHC complexes do not persist at later times 
(Mintern, Bedoui et al. 2009).  
The prototypic herpesvirus Epstein Barr virus (EBV) is a ubiquitous human γ-herpesvirus that 
establishes persistent infection in more than 90% of the human adult population (Young and 
Rickinson 2004). The encounter of EBV during childhood results usually in asymptomatic 
infection, while during adolescence it causes infectious mononucleosis in 30-70% of cases 
(Auwaerter 1999; Tattevin, Le Tulzo et al. 2006). Additionally, EBV is the first virus discovered to 
be associated with human malignancies such as Burkitt lymphoma, Hodgkin lymphoma, and 
nasopharyngeal cancer (Ko 2015). Like other herpesviruses, EBV can undergo two infectious 
programs. During its latent state, EBV immortalized B are controlled by latent antigen-specific 
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CD8+T cells, and virus persistence is preserved. In the latent phase, 9 EBV genes are expressed as 
proteins: the EBV nuclear antigen family proteins (EBNA), which are comprised of EBNA1, -2, -3A, 
-3B, and -3C, the leader protein (LP), and latent membrane protein (LMP)-1, -2A, and -2B 
(Babcock, Hochberg et al. 2000; Thorley-Lawson 2001). However, herpesviruses occasionally 
undergo reactivation into their lytic cycle, where EBV expresses in a time-programmed manner a 
large number of lytic viral proteins (Miller, El-Guindy et al. 2007). The first genes to be transcribed 
are the immediate early lytic genes BZLF1 and BRLF1, which initiate the transcription of the more 
than 80 other lytic genes (Feederle, Kost et al. 2000). What exactly triggers the reactivation of the 
lytic cycle in vivo is not known yet. Nevertheless, it has been shown that differentiation of infected 
B cells into plasma cells could result in the latent-to-lytic switch (Babcock, Hochberg et al. 2000). 
Besides expression of different sets of genes, latent and lytic viral states also differ with respect to 
cells and their localization. Both latent and lytic antigens are expressed in B-lymphocytes within 
lymphoid tissue, but lytic antigens are mainly expressed in epithelial cells of the oropharynx tract 
(Hadinoto, Shapiro et al. 2009). Presentation of EBV in the context of MHC-I with the consequent 
activation of CD8+T cells plays an important role in controlling EBV infection and in deciding the 
outcome of the EBV infection. Indeed, restoration of T cell compartment in immunodeficient 
individuals, protect them from the high frequency of EBV-induced disease (Tangye, Palendira et al. 
2017). During the latent phase, strong CD8+T cell response to immunodominant epitopes derive 
mainly from EBNA3 proteins, and with lesser extent from EBNA2 and LMP2. CD8+T cells specific 
for LMP1 and EBNA-LP antigens have been detected rarely (Hislop, Ressing et al. 2007; Brooks, 
Long et al. 2016). Additionally, in spite of the immune evasion ability, EBNA1 epitope-specific CD8+ 
T cell responses could be detected in virus-immune donors, and could be immunodominant in the 
context of certain HLA class I alleles, for example B*3501 (Blake, Haigh et al. 2000). As cells 
progressed through EBV’s lytic cycle, the MHC-I levels and TAP function decrease due to specific 
immune escape mechanisms of EBV lytic cycle proteins targeting the HLA class I pathway (See 
1.1.6). CD8+T specific for lytic cycle proteins have been identified in infectious mononucleosis 
settings were the specificities were mainly directed against immediate-early proteins, BZLF1 or 
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BRLF1, or to early BZLF1-/BRLF1-induced proteins, such as BMLF1, BMRF1, BALF2, or BALF5 
(Hislop and Taylor 2015). It is interesting to note that BZLF1 seems to be the most immunogenic 
protein, as it could be the result of an evolution of the immune system to ensure a proper control 
of the virus replication and of its spread within the host (Houssaint, Saulquin et al. 2001). 
One of the best-characterized systems used to investigate CD8+T cell function during both acute 
and chronic infection is lymphocytic choriomeningitis virus (LCMV). LCMV is a murine specific 
virus, which results in either acute or chronic infection, depending on the virus strain. Indeed, the 
Armstrong strain causes acute infections while its clone 13 variant is responsible for chronic 
infection. It has been shown that clearance of LCMV infection is dependent on CD8+ T cells and β2-
microglobulin as mice depleted for their CD4+T cell compartment were still able to resolve LCMV 
infection as good as control mice, while β2-microglobulin knock-out mice were not (Matloubian, 
Concepcion et al. 1994). During acute infection, the majority of LCMV-specific CD8+T cells found in 
the spleen were against the glycoprotein (GP33-41) and the nucleoprotein (NP396-404) presented on 
the MHC-I molecules H2-Db and H2-Kb to CD8+ T cells (Murali-Krishna, Altman et al. 1998). CD8+ T 
cell specificities for other epitopes within those two proteins have been found as well (Appay, 
Nixon et al. 2000; Goepfert, Bansal et al. 2000). After resolution of infection, the effector T cell 
populations can either be eliminated via a cell death program called apoptosis, or become a pool of 
memory T cells ready to fight the virus again in case of a new infection (Kaech, Wherry et al. 2002). 
On the other hand, LCMV chronic infection persists for a maximum of 3 months. It causes 
suppression of CD8+T cell response and relocalization of the virus-specific CD8+T cells to non-
lymphoid organs and bone marrow (Wherry, Blattman et al. 2003).  
Thus, presentation of viral antigen by MHC-I molecules is indispensable for the host protection 
against viruses and for the efficient activation of CD8+T cells. As counteracting mechanisms, 
viruses have evolved strategies to block the associated processes, as will be discussed in the next 
section. 
Introduction – Part I 
14 
 
1.1.6 Virus evasion of MHC class I presentation pathway 
Viruses need a host for their life cycle, in order to replicate and spread. As discussed above, the 
host is equipped with defence mechanisms against viral infections such as viral antigen 
presentation on MHC-I. In turn, viruses have developed mechanisms of immune evasion by 
acquiring proteins able to alter the classical MHC-I biogenesis, trafficking and presentation. 
Indeed, some viral immunoregulatory proteins have been acquired from the host, while some 
others without sequence similarities to host genes have probably developed de novo as a result of 
evolutionary pressure (Alcami and Koszinowski 2000).  
Viruses evade the MHC-I pathway at different levels (Figure 1.6). Some viruses, mainly 
herpesviruses, divert MHC-I molecules to degradation. For example, US2 and US11 proteins of the 
human cytomegalovirus as well as the mK3 protein of mouse herpesvirus 68 target the new MHC-I 
molecules to ER-associated degradation (Wiertz, Jones et al. 1996; Gewurz, Wang et al. 2001). On 
the other hand, endocytosed MHC-I degradation by lysosomal proteases results from their 
internalization induced by E3 ubiquitin ligases kK3 and kK5 of KSHV (Coscoy, Sanchez et al. 2001; 
Duncan, Piper et al. 2006) as well as new MHC-I molecules are redirected from the Golgi to 
lysosomes by the human immunodeficiency virus protein Nef (Schaefer, Wonderlich et al. 2008) 
and the murine cytomegalovirus protein gp48 (Reusch, Muranyi et al. 1999). A different strategy 
for viral immunoevasion is the inhibition of PLC components causing low peptide availability and 
an inefficient MHC-I loading. TAP activity is indeed inhibited by the action of several viruses such 
as the herpes simplex virus protein ICP47, the human cytomegalovirus protein US6 and the 
BNFL2a protein of Epstein Barr virus, which bind to and inhibit TAP activity (Lehner, Karttunen et 
al. 1997; Neumann, Kraas et al. 1997; Hislop, Ressing et al. 2007). Moreover, the human 
cytomegalovirus protein US3 inhibits tapasin-dependent peptide loading and peptide optimization 
(Park, Kim et al. 2004). Finally, the mature MHC-I molecules are retained within the ER by 
adenovirus E3-19K and cowpox CPXV203 proteins (Flomenberg, Szmulewicz et al. 1992; Byun, 
Wang et al. 2007). 
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Figure 1.6 Viral Immunoevasion 
Immune escape mechanisms for some viruses are depicted. Epstein-Barr nuclear protein 1 (EBNA1) and KSHV latency-
associated nuclear antigen 1 (LANA1) inhibit their own degradation by the proteasome. US2 and US11 of human 
cytomegalovirus (HCMV), and mK3 of mouse herpesvirus 68 (MHV68) target new MHC-I molecules to ER-associated 
degradation (ERAD). Different steps of peptide transport by TAP are inhibited by herpes simplex virus (HSV) ICP47, HCMV 
US6, by the BNFL2a protein of Epstein Barr virus and by the UL49.5 proteins of bovine herpesvirus 1. Mature MHC-I 
molecules are retained in the ER by the adenovirus E3-19K and the HCMV US3. Differently, kK3 and kK5 of Kaposi’ sarcoma-
associated herpesvirus (KSHV), Nef of human immunodeficiency virus (HIV-1) and gp48 of murine cytomegalovirus (MCMV) 
target MHC-I to lysosomes for degradation. 
However, down-regulation of MHC-I molecules has a drawback. While it offers protection from 
CD8+T cells, it renders them susceptible to natural killer (NK) cells since MHC-I molecules 
expression inhibits NK cells. Nevertheless, viruses, such as human and mouse cytomegaloviruses, 
have evolved also NK cell recognition evasion, by encoding MHC-I-like ligands for inhibitory NK 
receptors (Voigt, Forbes et al. 2003; Prod'homme, Griffin et al. 2007). 
Viruses can also target the proteasome degradation and the mRNA translation. Indeed, the EBV 
protein EBNA1 escapes processing by the proteasome due to the presence of glycine and alanine 
repeats (GAr) that interfere with the recognition and unfolding functions of the 26 S proteasome 
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(Daskalogianni, Apcher et al. 2008). Moreover, thanks to the same motif, EBNA1 inhibits 
translation of its own transcript by blocking the assembly of the EBNA1 translating ribosomes 
upon GAr synthesis (Yin, Manoury et al. 2003; Apcher, Komarova et al. 2009). Interestingly, the 
Kaposi’ sarcoma-associated herpervirus latency-associated nuclear antigen 1 has a highly 
repetitive acidic sequence that is rich in glutamine, glutamic acid and aspartic acid residues with a 
similar inhibitory ability to that of EBNA1 (Kwun, da Silva et al. 2007; Apcher, Komarova et al. 
2009). 
Thus, it is important to understand how viruses evade the immune recognition by disrupting 
the classical MHC-I presentation in order to counteract such mechanisms and improve therapeutic 
approaches to boost the adaptive immune response against viral pathogens by allowing MHC-I-
restricted viral antigen presentation via alternative pathways, and consequently thereby 
promoting CD8+ cytotoxic T cell activity for effective viral clearance.  
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Part II - Autophagy 
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1.2.1 Autophagy pathways 
Autophagy (form the Greek autóphagos, meaning "self-devouring") is a fundamental, 
evolutionary well conserved set of catabolic pathways that deliver cytoplasmic cargoes to the 
lysosome for degradation and recycling (Deter, Baudhuin et al. 1967; Deter and De Duve 1967). 
Originally, autophagy was described as a non-specific pathway, important during starvation to 
ensure supply of nutrients, while more recent evidence has shown that autophagy is also 
involved in the selective sequestration and degradation of cytoplasmic cargoes such as 
organelles, unfolded proteins, and pathogens. Furthermore, autophagy is involved in various 
cellular processes and a variety of disorders have been associated with dysfunctional 
autophagy in humans (Rubinsztein 2006; Qu, Zou et al. 2007; Cecconi and Levine 2008; Levine 
and Kroemer 2008; Saitoh, Fujita et al. 2008; Deretic and Levine 2009; Deegan, Saveljeva et al. 
2013; Chhangani, Chinchwadkar et al. 2014). 
Three different forms of classical (or canonical) autophagy can be distinguished in 
eukaryotic cells: microautophagy, chaperone-mediated autophagy (CMA), and macroautophagy. 
While microautophagy, known as endosomal microautophagy in mammals (Mukherjee, Patel et 
al. 2016), engulfs cytosolic proteins through invagination of the lysosomal or late endosomal 
membrane, during CMA, substrates containing a specific motif are recognized by the cytosolic heat 
shock protein 70 (HSP70) and translocated into lysosomes via lysosome-associated membrane 
protein 2a (LAMP2a). In both pathways the final stage is the degradation of the translocated 
material in lysosomes (Figure 1.7). Macroautophagy is the most studied form of autophagy, and 
as such often the term autophagy refers to macroautophagy. In this process, cytoplasmic 
substrate gets enclosed in a double-membrane vesicle, the autophagosome (Xie and Klionsky 
2007), which fuses with the lysosome resulting in cargo degradation (Yang and Klionsky 2010) 
(Figure 1.7). In addition to the classical autophagy pathways, other pathways referred to as 
non-canonical autophagy that exploit sets of proteins of the autophagy machinery have been 
described. Examples are: LC3-associated phagocytosis (LAP)(Sanjuan, Dillon et al. 2007), Beclin 
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1-independent autophagy (Tian, Lin et al. 2010), Golgi-related autophagy (Nishida, Arakawa et al. 
2009), and nuclear membrane-derived autophagy (English, Chemali et al. 2009). 
 
Figure 1.7 Schematic representation of the three forms of canonical autophagy.  
During microautophagy or endosomal microautophagy in mammals (A) cytoplasmic material is taken up into the 
lysosome by membrane invagination. In chaperone-mediated autophagy (B) unfolded proteins are directly transported 
into lysosomes by the lysosomal chaperonin HSC70 and LAMP2a. (C) Macroautophagy involves the formation of a cup-
shaped isolation membrane, also called phagophore, that encloses a portion of the cytoplasm. All forms of autophagy 
subsequently lead to the degradation of cytoplasmic constituents by lysosomal hydrolases. 
1.2.2 Molecular mechanism of macrautophagy and its regulation 
In mammals, a mature autophagosome forms in 5-10 minutes and it is about 0.5-1.5µm in 
diameter (Mizushima, Yamamoto et al. 2001; Fujita, Itoh et al. 2008). The formation of 
autophagosomes and its molecular machinery has been described first in yeast and requires a 
number of proteins called autophagy-related gene (Atg) products. More than 30 Atgs have been 
identified in yeast and many of them have orthologues in mammals (Figure 1.8). For the initial 
characterization of this machinery, Dr. Yoshinori Ohsumi has been awarded the Nobel Prize in 
physiology and medicine last year (Levine and Klionsky 2017). During the initiation of the 
autophagic process, the phagophore or isolation membrane is formed. The source of the 
membrane to form the autophagosome is under intense debate. Likely, it depends on the 
location of the substrates. The most probable sources are membranes derived from the ER, 
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Golgi, plasma membrane and mitochondria (Tooze and Yoshimori 2010). Autophagy is 
regulated by several mechanisms such as nutrient starvation, hypoxia and reactive-oxygen species 
(ROS) (He and Klionsky 2009). For example, the level of nutrients controls the phagophore 
formation by two energy-sensing kinases: the mammalian target of rapamycin (mTOR), and 
specifically the mTORC1 complex, functions as autophagy inhibitor, while the AMP‐activated 
protein kinase (AMPK) triggers autophagy (Hardie 2011). 
The formation of autophagosome is a complicated, highly regulated and specific interplay of 
different protein complexes. Conventionally, the autophagy process is divided into 5 steps: 
initiation, nucleation, elongation, closure and fusion. The initiation step occurs at the site of the 
isolation membrane formation, and starts with the assembly and activation of a serine-threonine 
kinase multiprotein complex called ULK complex containing ATG13, ATG101, FAK family kinase 
interacting protein of 200 kDa (FIP200) and unc‐51‐like autophagy activating kinase 1 (ULK1, the 
mammalian orthologue of yeast Atg1) or ULK2. The site of autophagy initiation is still under 
investigation. Recently, it has been described that ULK1 complexes are recruited to ER regions that 
are marked with ATG9 (Karanasios, Walker et al. 2016). The ULK complex recruits the 
multiprotein complex of the class III phosphatidylinositol 3‐kinase (PI3K) for the nucleation step. 
This complex comprises beclin 1, vacuolar protein sorting (VPS) 34, VPS15, ATG14, which serves 
as sensor of membrane curvature, and the nuclear receptor-binding factor 2. The PI3K complex 
produces phosphatidylinositol 3-phospate (PI3P) which recruits and stabilizes some core 
autophagy proteins such as WD-repeat domain phosphoinositide-interacting (WIPI1-4) family and 
helps in the curvature of autophagosomes. Among WIPI proteins, WIPI-2 recruits the autophagy 
machinery responsible for the elongation phase, such as ATG16L1 (Proikas-Cezanne, Takacs et al. 
2015). The elongation step is regulated by two ubiquitin-like protein conjugation systems: 
ATG16L1 complex and ATG8. The former complex comprises ATG16L1, ATG12 and ATG5. 
ATG12 is conjugated to ATG5 by ATG7 and ATG10 (Nakatogawa, Suzuki et al. 2009). ATG16L1 
then associates with ATG5 and this complex mediates the elongation of the autophagosomal 
membrane and the incorporation of ATG8 into the autophagosomal membrane (Ohsumi 2001). 
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ATG8 is the yeast orthologue of a family of mammalian proteins that comprises LC3A-C, 
GABARAP, and GABARAPL1-3. LC3B is the principle ATG8 orthologue studied, and from now on 
I will refer to LC3B as LC3. LC3 undergoes different catalytic steps. First, the cytosolic precursor 
of LC3 is cleaved by the cysteine protease ATG4 to become LC3-I, known also as cytosolic LC3. 
Subsequently, ATG7 and ATG3 activate LC3-I in an ATP-dependent manner, making it a suitable 
substrate for the ATG16L1 complex. Indeed, the ATG16L1 complex conjugates the cytosolic 
LC3-I to the phospholipid phosphatidylethanolamine, resulting in the formation of the lipidated 
form of LC3, or LC3-II, which is integrated into the autophagosomal membrane (Fujita, Itoh et 
al. 2008). The role of LC3-II is still under discussion. It was believed to play a role in elongation 
and in the sealing of the autophagosome, while recently it has been shown that in absence of 
ATG3 and LC3 autophagosomes can close, even if smaller, and LC3 seems to be indispensable 
for fusion event (Nguyen, Padman et al. 2016) and proper degradation of the cargo 
(Tsuboyama, Koyama-Honda et al. 2016). LC3-II locates to both the outer and the inner 
membrane of the autophagosome. While LC3-II at the outer membrane gets cleaved from 
phosphatidylethanolamine by ATG4 upon autophagosome closure, LC3-II residing in the inner 
membrane gets degraded together with the cargo within lysosomes. Therefore, LC3 is widely 
used as autophagy marker and as indicator of the autophagic flux, indicating the rate of 
recruitment, segregation and degradation of autophagy substrates (Loos, du Toit et al. 2014).  
Once autophagosomes close, they can fuse with late endosomes or lysosomes to form 
amphisomes or autolysosomes, respectively (Gordon and Seglen 1988; Klionsky, Eskelinen et 
al. 2014). Similar to other vacuole membrane fusion events, fusion of the autophagosome with 
the lysosome is thought to be mediated by Rabs and SNAREs but the exact mechanism is still 
under intense investigation.  
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Figure 1.8 Macroautophagy  
Upon signals for initiation of macroautophagy, the isolation membrane is formed followed by a cascade activation of 
the ULK1 complex and the PI3K complex. ATG12 is conjugated to ATG5 by ATG7 and ATG10. ATG16L1 then associates 
with ATG5 and this complex mediates the elongation of the autophagosomal membrane. In addition, LC3 is cleaved by 
cysteine protease ATG4 to become LC3-I. Subsequently, ATG7, ATG3 and the ATG16L1 complex conjugate free cytosolic 
LC3-I to phosphatidylethanolamine (PE) to become LC3-PE (LC3-II) that associates with autophagosomes. The resulting 
isolation membrane expands and engulfs a portion of the cytosol, including entire organelles. Upon closure of the double 
membrane surrounded autophagosome, the ATG12-ATG5-ATG16L1 complex dissociates and LC3 is cleaved by ATG4 
from the outer autophagosomal membrane, while lipidated LC3 (LC3-II) remains bound to the inner autophagic 
membrane with which it is degraded, together with the cargo, after fusion with the lysosome. 
It is worth noting that the study of the autophagy pathway is still challenging for the 
scientific community as autophagy is a dynamic and complex process, requiring interactions 
among several proteins. Moreover, selective pharmacological inducers and inhibitors  of 
autophagy are lacking. The main accepted drugs are Bafilomycin A and chloroquine, which 
inhibit lysosomal fusion and acidification, respectively, causing an accumulation of LC3-II. On 
the other hand, as inducers, rapamycin, which inhibits mTOR, and starvation are the most 
widely used. Molecular biology-based approaches could overcome the lack of specificity in 
these approaches, even if they might induce compensatory mechanisms in the affected cellular 
or animal systems. Indeed, the silencing or the genetic removal of components of the different 
autophagy complexes has been developed for both in vitro and in vivo applications. 
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1.2.3 Selective autophagy and LIR motif 
As mentioned above, despite autophagy being initially described as a non-selective process, it is 
now clear that selected cargo can be specifically degraded by autophagy. Indeed, the term selective 
autophagy refers to the degradation of targeted organelles or pathogens and each type of selective 
autophagy has been named after the targeted substrate (e.g. mitophagy for mitochondria 
degradation, xenophagy for bacteria and virus degradation). Moreover, autophagy substrates can 
be selectively recognized by specific receptors (Farre and Subramani 2016). By definition, 
autophagy receptors are “proteins that recognize and bind autophagy substrates, allowing their 
engulfment within the autophagic vesicles, and become degraded within lysosomes in the course 
of functional autophagic responses” (Galluzzi, Baehrecke et al. 2017). Most autophagy receptors 
are characterized by the presence of a specific motif called LC3‐interacting region (LIR) (Table 
1.1) and some, for instance p62, have an ubiquitin-binding domain allowing engulfment of 
ubiquitinated substrates (Khaminets, Behl et al. 2016). Interestingly, some receptors not only 
target autophagy substrates to form autophagosomes upon LC3 binding, but have also regulatory 
functions (Kimura, Jain et al. 2015; Verlhac, Gregoire et al. 2015).  
LIRs have been recently characterized (Jacomin and Nezis 2016) as a consensus sequence of 6 
amino acid residues in length. Within the sequence, the aromatic and the hydrophobic residues in 
position 3 and 6, respectively, are the most crucial determinants (Alemu, Lamark et al. 2012). In 
addition, a non-conventional LIR, lacking the aromatic residue, has been identified within the 
autophagy receptor nuclear dot protein 52 (NDP52), and can specifically interact with LC3C (von 
Muhlinen, Akutsu et al. 2012). An additional mechanism by which cells regulate selective 
autophagy-mediated degradation could be the phosphorylation status of LIR motifs, since such 
modifications impair the interaction between LC3 and autophagy receptors (Rogov, Suzuki et al. 
2017). 
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Protein LIR position LIR sequence 
ATG19 406-415 NEKALTWEEL 
ATG32 80-91 DSISGSWQAIQP 
ATG34 402-412 TLSRPFTWEEL 
BNIP3L 30-44 AGLNSSWVELPMNSS 
FUNDC1 6-26 YESDDQSYEVLDLTEY 
NBR1 724-738 QSSASSEDYIILPE 
NDP52 126-140 RPENEEDILVVTTQG 
OPTN 169-184 NSSGSSEDSFYEIRMA 
p62 330-345 NCSGGDDDWTHLSSKE 
TAX1BP 135-147 EGENSDVLVVTTKA 
 Table 1.1 List of LC3-interacting regions (LIRs).  
Positions from 3 to 6 of the LIR motif are in bold. ATG, autophagy-related protein; BNIP3L BCL2 interacting protein 3-like; 
FUNDC1, FUN14 domain containing 1; NBR1, neighbour of BRCA1 gene 1; NDP52, nuclear dot protein 52 kDa; OPTN, 
Optineurin; p62 or sequestosome 1; TAX1BP, Tax1 Binding Protein 1. 
Presence of LIR motifs has been reported also within components of the receptor 
internalization machinery linking autophagy to internalization process of plasma membrane 
molecules. 
1.2.4 ATGs in receptor internalization 
Links between autophagy and the clathrin-mediated internalization machinery have been 
reported. Indeed, clathrin contains a LIR motif and clathrin-mediated endocytosis has been shown 
to support autophagosome formation (Ravikumar, Moreau et al. 2010). Moreover, the adaptor 
protein 2 (AP2), a component of the machinery implied in clathrin-mediated endocytosis, was 
shown to function as autophagy receptor for the trafficking of the Alzheimer's amyloid protein 
precursor from the plasma membrane to the autophagosomes for degradation (Tian, Chang et al. 
2013). Moreover, recently, the non-classical MHC-I molecules, CD1d, has been shown to be 
internalized by a clathrin-mediated endocytosis process dependent on Atg5 (Keller, Loi et al. 
2017). Interestingly, the tyrosine motif recognized during clathrin-dependent endocytosis has 
been found within the MHC-I sequence and studies have reported its importance for proper 
internalization and trafficking during cross-presentation (Lizee, Basha et al. 2003; Basha, Lizee et 
al. 2008). Thus, it is tempting to speculate about a role of the autophagy machinery in the 
regulation of MHC-I internalization via its interactions with the clathrin-dependent endocytosis 
machinery.  
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1.2.5 ATGs in antigen presentation 
Among the various roles of autophagy, several studies have shown that autophagy is also 
involved in both innate and adaptive immune responses. Autophagy has been identified as a 
regulator of antigen presentation of cytosolic (Paludan, Schmid et al. 2005; Schmid, Pypaert et al. 
2007) and extracellular proteins (Romao, Gasser et al. 2013) for MHC-II presentation. On the 
contrary, the role of autophagy in MHC-I presentation has only been poorly described. 
As mentioned earlier, MHC-II molecules serve classically as platform to present extracellular 
antigens to CD4+T cells, but biology does not lack exceptions. Indeed, MHC-II can also present 
cytosolic antigens via alternative pathways, such as autophagy. It has been shown that 
autophagosomes fuse with the MHC-II loading compartments (MIICs) in human B cells, DCs and 
epithelial cell lines, as well as in mouse thymic epithelial cells, and that fusing proteins to the N-
terminus of LC3 enhances MHC-II presentation of viral and tumour antigens up to 20 fold (Schmid, 
Pypaert et al. 2007; Kasai, Tanida et al. 2009). Processing of endogenous MHC-II antigens via 
macroautophagy promotes presentation of intracellular antigens to CD4+T cells contributing to the 
thymic selection of the CD4+ T cell repertoire (Nedjic, Aichinger et al. 2008). In contrast, exogenous 
antigen processing for MHC-II presentation benefits from the autophagy machinery via LAP, a non-
canonical form of autophagy. During LAP, phagosomes get coated with LC3 and require ROS 
production by NADPH oxidase, NOX2, to acquire or maintain this coat (Martinez, Malireddi et al. 
2015). Depending on the cellular context, phagosome-associated LC3 seems to accelerate fusion 
with lysosomes in mouse macrophages (Sanjuan, Dillon et al. 2007), or preferentially fuse with 
compartments containing pathogen-associated molecular pattern receptors (Henault, Martinez et 
al. 2012). In contrast, in human macrophages and DCs, LAP vesicles seem to be stabilized and 
maintain antigen, resulting in prolonged MHC-II presentation (Romao, Gasser et al. 2013). Thus, 
the autophagy pathways seem to support both endogenous as well as exogenous antigen 
processing for MHC-II presentation via canonical and non-canonical autophagy, respectively. A 
role of autophagy in MHC-II via its fusion with the endosomal-loading compartment is not 
surprising as autophagosomes fuse with late endosomes to form amphisomes before the final 
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fusion with lysosomes (Berg, Fengsrud et al. 1998). In contrast to this supportive role for MHC-II 
restricted antigen presentation, a role for autophagy in classical MHC-I antigen presentation is not 
obvious given that the endogenous MHC-I antigen presentation pathway does not seem to 
intersect with the autophagosomal route. Therefore, the role of autophagy in MHC-I antigen 
presentation is still controversial. Despite the large body of evidence that suggests autophagy does 
not play a role in MHC-I antigen presentation, there are some reports supporting its involvement. 
Indeed, it has been shown that autophagy’s contribution to MHC-I presentation become important 
when the classical MHC-I pathway is impaired by viral proteins, as described in section 1.1.6, for 
example by herpesviruses. It has been shown that during herpes simplex virus 1 infection, the viral 
envelope glycoprotein B is presented on MHC-I in an autophagy-dependent manner at late time 
points during infection (English, Chemali et al. 2009). Moreover, in cells defective for the TAP 
protein responsible for the translocation of peptides from the cytosol to the ER in the classical 
MHC-I pathway (See 1.1.3), the latent viral protein pUL138 of human cytomegalovirus was 
presented to CD8+ T cells by an autophagy-dependent pathway (Tey and Khanna 2012). In the 
same condition, the autophagy pathway CMA has been shown to play a role in the presentation of 
endogenous antigen such as the truncated forms of the Simian virus 40 (SV40) large T antigen 
(Schirmbeck, Bohm et al. 1997). Therefore, autophagy clearly serves to overcome viral immune 
escape mechanisms, providing an alternative pathway to alert the immune system about the 
presence of viruses within cells. 
In other contexts, further evidence supports a possible role of autophagy in MHC-I presentation 
of endogenous antigens. For example, the induction of autophagy during mycobacterium 
tuberculosis infection increases the proliferation of CD8+ T cells (Jagannath, Lindsey et al. 2009). 
Similarly, autophagy degradation of tumour antigen aggregates enhances MHC-I presentation of a 
melanoma-derived peptide, resulting in CD8+ T lymphocyte proliferation and decreased tumour 
growth in vivo (Fu, Tao et al. 2010). Thus, besides being a valid strategy to fight viruses, autophagy 
enhances the immune defence mechanisms against bacterial pathogens and tumours. 
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Under debate is also the role of autophagy in cross-presentation. Some studies have shown that 
in professional antigen presenting cells, autophagy can provide antigens for cross-presentation 
and helps in their packaging for their delivery to antigen presenting cells (Li, Wang et al. 2008; Uhl, 
Kepp et al. 2009). Interestingly, in cross-presenting subsets of DCs, autophagic membrane 
formation is most pronounced and ATG7 is required for efficient presentation of soluble protein, 
but not of antigen targeted to the endocytic receptor DEC-205 on DCs or of antigen incorporated 
into apoptotic cell debris (Mintern, Macri et al. 2015). In line with this, the involvement of 
autophagy in the cross-presentation of the soluble human cytomegalovirus antigen pp65 has also 
been demonstrated (Dasari, Rehan et al. 2016). 
Thus, autophagy actively supports and provides alternative mechanisms to ensure immune cell 
control of infections that compromise classical antigen processing for MHC-I presentation. It is 
therefore not surprising that in turn, viruses have evolved mechanism to manipulate autophagy.  
1.2.6 Regulation of autophagy by viruses 
Autophagy is an anti-viral mechanism and as such viruses have evolved mechanisms to 
manipulate it. The interplay between autophagy and viruses is still under investigation as viruses 
can in some cases block autophagy or use it for their own benefits. Autophagy, playing a role in the 
process of antigen presentation, contributes, indeed, to help the host immune system to fight 
viruses. For example, for some herpes viruses it has been suggested that the inhibition of 
autophagy by viruses is required for their efficient replication (A. Orvedahl, et al, 2011; G.H. Jang et 
al. 2016) and also for the development of viral oncogenesis for EBV (Deretic and Levine 2009) as 
the inhibition of autophagy further limit adaptive immune response of the host. Therefore, it is 
important to understand how viruses interfere with autophagy to develop strategies to block 
them. Viruses have evolved several ways to manipulate autophagy mainly at two levels. As 
depicted in Figure 1.9, some viruses have been found to interfere with autophagosome formation, 
while others mainly regulate autophagosome fusion with lysosomes (Paul and Munz 2016).  
Introduction – Part II 
28 
 
At initial phases of autophagy the protein mainly targeted by herpesviruses is beclin1 but many 
viruses have usually more than one mechanism to evade the same or different steps of the 
autophagy pathway. For example, herpes simplex virus 1 blocks beclin1 via both ICP34.5 and US11 
(Orvedahl, Alexander et al. 2007; Lussignol, Queval et al. 2013). On the other side, Kaposi’ 
sarcoma-associated herpes virus uses its Bcl-2 orthologue and the viral FLICE-like inhibitory 
protein to inhibit beclin1 and the LC3 lipidation step by targeting ATG3, respectively (Lee, Li et al. 
2009).  
Interestingly, the two viruses used in the present PhD thesis, the Influenza A virus (IAV) and 
EBV provide example of the dual manipulation of autophagy. More specifically, IAV ion-channel 
protein M2 interacts with LC3 thanks to its LIR motif. This binding causes on one hand the 
accumulation of autophagosomes by inhibiting their fusion with the lysosome (Gannage, Dormann 
et al. 2009) and on the other hand results in the re-localization of LC3 at the plasma membrane of 
the infected cells rendering virus particles more stable and thus, enhancing virus transmission 
(Beale, Wise et al. 2014). 
 
Figure 1.9 Viral inhibition of autophagy.  
Viruses can inhibit autophagy mainly at two stages: the formation of autophagosomes (such as Kaposi’s sarcoma 
associated herpesvirus (KSHV), murine γ-herpesvirus 68 (MHV68), herpes simplex virus-1 (HSV-1), human 
cytomegalovirus (HCMV), and Epstein Barr virus (EBV)) and the fusion of autophagosome with lysosomes (influenza A 
virus (IAV), polio, and HIV).  
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Similarly, the Bcl-2 homologues, BamHI rightward fragment 1 (BHRF1) and BamH1 A leftward 
fragment 1 (BALF1) of EBV might be responsible for blocking autophagy by inhibiting beclin1 
(Coleman, McGraw et al. 2014; De Leo, Colavita et al. 2015). At the same time, EBV exploits the 
autophagic membranes for its exocytosis from infected cells (Nowag, Guhl et al. 2014). Moreover, 
LMP1 and LMP2 protein of EBV prevent cell death by inducing autophagy (Lee and Sugden 2008; 
Fotheringham and Raab-Traub 2015; McFadden, Hafez et al. 2016).  
Thus, it is clear that autophagy plays an important role in the life cycle of some viruses. As such, 
it is of great importance to understand how to exploit the molecular machinery of autophagy, as 
alternative mechanism against viruses, especially for those that are invisible to the immune system 
thanks to their ability to inhibit the classical MHC-I pathway. 
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This study aims at elucidating how autophagy influences antigen processing, vesicular MHC-I 
loading and trafficking. Since knowledge on the mechanism of viral antigen presentation is crucial 
for rational vaccine design, these studies might help to improve the adaptive immune response 
against viral pathogens via manipulation of autophagy proteins. In addition, understanding how 
autophagy regulates antigen presentation to T cells could facilitate the generation of therapeutic 
approaches that promote CD8+ cytotoxic T cell activity against pathogens. The gained information 
will allow the regulation of CD8+ T cell stimulation via autophagy and they may open an interesting 
perspective for application of innovative strategies for vaccination. 
With the above-mentioned purpose, the proposed thesis deals with the role of the molecular 
machinery of autophagy in the regulation of MHC-I surface levels and antigen presentation both in 
vitro and in vivo. In particular, the role of the autophagy machinery in MHC-I stabilization on 
antigen presenting cells (Results part I) and in endogenous antigen presentation by MHC-I 
molecules I in vitro (Results part II) have been investigated. 
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3.1.1 Increased MHC class I levels on autophagy-deficient Atg5-/- or Atg7-/- DCs 
and macrophages in vitro and in vivo 
The catabolic process of autophagy has been linked to the process of antigen presentation 
for MHC-II but its role in the context of MHC-I is under investigation and still under debate. In 
order to address whether MHC-I presentation could be affected by autophagy deficiency we 
made use of Cre technology to obtain mice in which specific autophagy key genes, namely Atg5 
or Atg7, were deleted in antigen presenting cells. Atg5 is a component of the ATG16L1 complex 
required for autophagosome formation, while Atg7 is required for the formation of the 
ATG16L1 complex as well as for LC3 lipidation. Specifically, in our mouse model Cre is under 
the control of the CD11c promoter, a marker expressed by all dendritic cells (DCs). Cre is a 
recombinase enzyme able to recognize and recombine floxed gene sequences. In our mice such 
sequences were at the flanking region of Atg5 or Atg7 gene leading to deletion of the gene of 
interest upon Cre expression by DCs. These mice are referred to as Atg5-/- or Atg7-/- DC mice, 
respectively.  
In the above-described animal model, we first analysed the surface levels of the MHC-I 
molecules H2-Kb and H2-Db on Atg5 deficient DCs from lung, spleen and bone marrow-DCs (BM-
DCs) by flow cytometry. Different subsets of DCs have been distinguished based on their surface 
markers such as CD11b, for both lung and spleen, CD103 and CD8 for lung and spleen, 
respectively. We found that in the lung Atg5-/- alveolar macrophages, CD11b+ and CD103+ DCs 
displayed higher MHC-I cell surface expression at steady state than in their Atg5flox/flox 
littermates (Figure 3.1 A-B). 
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Figure 3.1 Elevated MHC class I expression on Atg5 deficient DCs and macrophages.  
Expression of H2-Db and H2-Kb on lung and splenic Atg5-/- and Atg5+/+ DCs and macrophages. Lung DCs were 
gated as live CD11c MHC-IIhigh cells. DC subsets were further subdivided on the basis of CD11b and CD103expression, and 
alveolar macrophages as double negative CD11b-CD103- cells. Inflammatory DCs and monocytes were gated out using 
Ly6C staining. Similarly, splenic DCs were gated as live CD11c+ MHC class IIhigh cells, excluding inflammatory DCs and 
macrophages by using both Ly6C and F4/80 staining. Graphs summarize mean fluorescence intensity (MFI) values and 
SEM of H2-Db in the lung (A) and in the spleen (C) from 3 independent experiments, each with 3 mice per group. Surface 
expression of H2-Kb in lung (B) and in the spleen (D) Atg5-/- and Atg5+/+ DCs and macrophages. Three experiments are 
summarized. P values are derived from unpaired non-parametric two tailed t test. 
Accordingly, in the spleen, both H2-Kb and H2-Db molecules of CD11c+ cells and specifically 
on both CD11b+ and CD8+ subsets of splenic DCs were expressed at significantly higher surface 
levels in Atg5-/- DC mice (Figure 3.1 C-D). Importantly, C57BL/6 wild-type and CD11c-cre 
transgenic C57BL/6 mice did not display the same phenotype (Figure 3.2). 
 
Figure 3.2 Elevated MHC class I expression is detected on Atg5 deficient DCs.  
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(A)  Surface expression of H2- Db on lung DC subsets for C57BL/6 wild type, CD11c-Cre, CD11c-cre x Atg5fl/fl and 
Atg5fl/fl mice. (B) Surface expression of H2- Db on splenic DC subsets for C57BL/6 wild type, CD11c-Cre, CD11c-cre x 
Atg5fl/fl and Atg5fl/fl mice. P values are derived from unpaired non-parametric two tailed t test.  
Moreover, Atg5 deficient BM-DCs displayed higher MHC-I levels than their wild-type 
counterparts (Figure 3.3A). In contrast, MHC-I surface expression was unchanged on B and T 
cells (Figure 3.3B).  
 
Figure 3.3 Elevated MHC class I expression on Atg5 deficient BM-DCs.  
Expression of H2-Db on Atg5+/+ and Atg5-/- BM-DCs. (A) Representative flow cytometric staining (left) and all 
summarized results (right) are derived from 5 independent experiments and are summarized as fold increase 
compared to Atg5+/+ DCs set as 100%. (B) MHC class I surface expression on B and T cells for the experiments of 3.1 
and 3.2. Mean and SEM were plotted. 
These data were confirmed in Atg7-/- DC mice where MHC-I levels were elevated on Atg7 
deficient alveolar macrophage and DC populations, but not B or T cells (Figure 3.4). 
 
Figure 3.4 Elevated MHC class I expression on Atg7 deficient lung and splenic DCs and macrophages.  
(A) Expression of MHC-I on Atg7+/+ and Atg7-/- alveolar macrophages. Results are from 6 independent experiments 
and are summarized as fold increase compared to Atg7+/+ macrophages. Unpaired non-parametric two tailed t tests 
were performed to obtain the indicated p values. (B) Surface expression of MHC-I on splenic Atg7+/+ and Atg7-/- DC 
subsets. (C) Surface expression of MHC-I on splenic Atg7+/+ and Atg7-/- B and T cells. 5 experiments are summarized.  
These findings suggest that deficiency in the core machinery of autophagy, which is required 
for LC3 lipidation, increases MHC-I levels on myeloid antigen presenting cells. 
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3.1.2 MHC class I transcription and transport to the cell surface are not altered in 
absence of autophagy 
In order to address the mechanisms that could lead to MHC-I up-regulation in the absence of 
autophagy, we tested four hypotheses (Scheme 3.1). 
 
Scheme 3.1 Four hypotheses tested  
Schematic representation of the 4 hypotheses tested to investigate by which mechanism autophagy deletion result in 
an increased MHC-I surface level on murine CD11c-expressing cells. 1. Investigation on transcription levels of MHC-I 
genes; 2. Evaluation of proteasomal degradation; 3. Analysis on the rate of assembly and trafficking to the cell surface of 
newly synthetized MHC-I molecules; 4. Quantification of the rate of internalization of MHC-I molecules. 
First, we ruled out a difference in MHC-I gene expression, by quantifying MHC-I transcript 
levels in flow cytometrically sorted splenic Atg5+/+ and Atg5-/- DCs (Figure 3.5A). Except for 
CD8+ splenic DCs that show a tendency towards increased H2-Kb transcription levels, no 
difference in MHC-I transcription was confirmed in the investigated lung and splenic DC and 
macrophage subpopulations (Figure 3.5B). These data indicate that the increased MHC-I 
surface expression of macroautophagy deficient DCs is not due to altered MHC-I gene 
transcription. We therefore addressed as the second hypothesis a difference in the availability 
of ubiquitinated substrates for proteasomal degradation and MHC-I loading. We could not 
detect any difference in the total amount of polyubiquitinated proteins in Atg5-/- DCs compared 
to Atg5+/+ DCs by Western blot quantification (data not shown). As the third hypothesis,  we 
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hypothesized the existence of a compensatory mechanism in the absence of degradation by 
autophagy. We considered an increased proteasome activity with a subsequent increase of 
MHC-I ligand production that could result in a faster assembly or transport to the cell surface of 
new peptide-MHC-I complexes (Dengjel, Hoyer-Hansen et al. 2012; Marshall, Li et al. 2015). 
However, we did not see any difference in the rate of de novo expression of MHC-I molecules on 
the cell surface as assessed after acid stripping, which denatures surface MHC-I molecules, 
followed by measuring the kinetics of MHC-I recovery at the cell surface (Figure 3.5C-D). As 
acid stripping influences MHC-I recovery at the surface by four different pathways, namely MHC 
class I synthesis, peptide loading in the ER, trafficking through the ER-Golgi secretory route and 
recycling through endosomes, these could be excluded as significant contributors to the 
described phenotype. These results taken together suggest that the higher surface expression of 
MHC-I molecules on Atg5-/- DCs is not related to enhanced gene transcription, increased 
availability of antigenic peptides, elevated synthesis or trafficking of de novo formed peptide-
MHC-I complex.  
 
Figure 3.5 Similar MHC class I transcription and transport to the cell surface in Atg5-/-deficient DCs. 
 (A) Quantification of MHC-I transcript levels in splenic Atg5+/+ and Atg5-/- DCs. H2-Kb mRNA levels were 
determined by qRT-PCR in FACS sorted splenic DCs. Fold change in H2-Kb mRNA of Atg5-/- cells compared to Atg5+/+ 
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cells is represented (values are calculated using the 2exp-ΔΔct formula). Data combine 3 independent experiments. 
(B) H2-Kb transcript levels in the indicated lung and splenic DC and macrophage populations. Data are from three 
mice per indicated experimental group. (C) and (D) Restoration of H2-Kb and H2-Db surface expression over time, in 
Atg5-/- and Atg5+/+ DCs after acid stripping of surface molecules. Graphs represent the mean of 3 independent 
experiments. 
3.1.3 Deficiency in the autophagy machinery compromises MHC class I 
internalization by DCs 
The fourth hypothesis explored a potentially attenuated internalization of MHC-I molecules 
in the absence of the autophagy core machinery. Indeed, we found that antibody labelled MHC-I 
molecules were internalized at a slower rate in Atg5-/- compared to Atg5+/+ DCs (Figure 3.6A-
D), increasing the difference in surface labelled H2-Db and H2-Kb molecules between Atg 
deficient and sufficient DCs over time (Figure 3.6A-B). Therefore, we concluded that a reduced 
internalization rate is responsible for higher surface expression of MHC-I molecules in Atg5-/- 
DCs and increased stability of MHC-I complexes on the cell surface. In good agreement with 
these findings, the total amount of MHC-I molecules was nearly two-fold higher in extracts of 
Atg5-/- splenic DCs than in the respective Atg5+/+ controls as determined by immunoblot 
quantification (Figures 3.6E), suggesting enhanced degradation of MHC-I molecules after 
internalization in the presence of the autophagy core machinery. Moreover, these data further 
exclude a possible role of a more efficient recycling in absence of autophagy and strengthen our 
conclusions on the central role of MHC-I internalization in our model, leading both to decreased 
internalization and degradation of MHC class I molecules. 
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 Figure 3.6 Atg deficiency compromises MHC class I internalization  
Internalization of MHC-I molecules over time in Atg5-/- and Atg5+/+ DCs. Cells were labelled with anti-H2-Kb (A) or 
anti-H2-Db (B), specific antibodies and incubated at 37°C for the indicated times. The rate of internalization at 37°C of 
H2-Kb molecules was evaluated by the decrease of MFI intensity compared to the MFI of control DCs incubated at 4°C 
and set as a reference to 100%. P values are from paired non-parametric two tailed t tests. Graphs (A and B) are the 
summary of 3 independent experiments. (C) and (D) The MFI ratio of H2-Kb surface staining on Atg5-/- compared to 
Atg5+/+ DCs increases over time during incubation at 37°C. Statistics were performed using paired non parametric 
two tailed t tests to compare the H2-Kb MFI ratio (log values) of time 0 to 30 min (p=0.015), to 60 min (p=0.01) and 
to 90 min (ns, not significant) (C) or the H2-Db MFI ratios (log values) of time 0 to 30 min (p=0.04), to 60 min 
(p=0.025) and to 90 min (ns, not significant)(D). (E) Immunoblot analysis of MHC-I protein content in Atg5-/- and 
Atg5+/+ splenic DCs. One representative immunoblot out of 5 is shown. Numbers below bands represent the ratio of 
normalized intensity of the MHC-I band compared to actin. (F) Summary of the MHC-I quantification, normalized to 
actin, for all five immunoblots as described in (E). 
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In order to determine if this loss of internalization in the absence of Atg5 also affected other 
surface receptors we tested the expression of CD29, CD44, transferrin receptor (TfR), the co-
stimulatory molecules CD80 and CD86, and MHC-II (Figure 3.7). Only CD80 seemed to be 
regulated in a similar fashion as MHC-I, as it showed a tendency towards stabilization on the 
cell surface of some Atg5-/- DC populations (mainly CD8+ splenic DCs, which could be in part due 
to an up-regulation of gene transcription as for MHC-I (Figure 3.5)), while the surface 
expression of the other investigated receptors was unchanged during steady-state as well as 
infection (Figure 3.7).  
 
Figure 3.7 Expression of most others surface receptors is not affected by the absence of Atg5. 
(A) Expression of surface receptors in splenic Atg5+/+ and Atg5-/- DCs. Splenic DCs were gated as live CD11c+ MHC-
IIhigh cells (GFP+ for Atg5-/- cells) and analysed for the expression of CD80, CD86, CD29, CD44 and transferrin receptor 
(TfR). Splenic DCs subsets were further divided on the basis of CD8 (B) and CD11b (C) expression. (D) MHC-II 
expression of the respective splenic DC subsets. Graphs represent the summary of MFI values from 7 independent 
experiments for CD80, CD86, CD29, MHC-II and 3 independent experiments for CD44 and transferrin receptor (TfR). 
Unpaired non-parametric two tailed t tests were used to obtain the displayed p values.  
Furthermore, we also observed that vesicular MHC-I pools could not be efficiently formed in 
alveolar macrophages and DCs of Atg5-/- and Atg7-/- DC mice (Figure 3.8). These data suggest 
that in absence of the autophagy machinery the MHC-I molecules are not efficiently internalized 
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and, in agreement with previous studies (Basha, Lizee et al. 2008; Nair-Gupta, Baccarini et al. 
2014), they are not efficiently shuttled to the endosomal compartment appropriate to cross-
presentation. 
 
Figure 3.8 Deficiency in autophagy machinery depletes intracellular pools of MHC class I molecules 
 Immune fluorescence staining for H2-Kb on Atg5+/+ and Atg5-/- lung CD11c+ cells (A) and MHC-I of Atg7+/+ and 
Atg7-/- BM-DCs (B). Counterstaining for nuclear DNA was performed with DAPI. One representative experiment is 
shown. Scale bar indicates 10 µm. (C) and (D) Quantification of vesicular (intracellular) MHC-I staining in Atg5+/+ and 
Atg5-/- lung CD11c+ cells and BM-DCs, respectively. The presented data summarize 4 independent experiments. P 
values are derived from unpaired non-parametric two tailed t tests.  
Finally, lysosomal degradation of MHC-I was also attenuated in Atg5 deficient BM-DCs 
(Figure 3.9). Indeed, upon treatment with chloroquine, a lysosomotrophic agent able to inhibit 
lysosomal degradation, MHC-I molecules accumulate in wild type cells but not in their 
autophagy deficient counterpart. In parallel LC3-II also accumulated only in Atg5 positive DCs. 
Thus, the autophagy machinery assists in internalization and it might help in the degradation of 
a subset of surface receptors, including MHC-I molecules, in DCs. 
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Figure 3.9 Lysosomal degradation of MHC class I is attenuated in absence of Atg5 
(A) Immunoblot analysis of MHC -I protein content in Atg5-/- and Atg5+/+ BM-DCs with and without chloroquine 
(CQ) treatment for 20 hours at concentrations of 25 and 50µM. One representative immunoblot out of 3 is shown. (B) 
Summary of the MHC-I quantification, normalized to actin, for all three immunoblots as described in (A). P values 
were determined by unpaired non- parametric two tailed t tests. 
3.1.4 Atg deficiency compromises MHC class I association with AAK1, which 
regulates MHC class I internalization 
In order to analyse the molecular mechanism by which the autophagy machinery assists 
MHC-I internalization and degradation, we immunoprecipitated MHC-I molecules from Atg5+/+ 
murine embryonic fibroblasts (MEFs) and analysed the results by mass spectrometry. We found 
two molecules that were previously reported to be involved in receptor-mediated endocytosis 
and degradation: the AAK1 (Conner and Schmid, 2002) and the Ral A binding protein 1 
(RALBP1) (Nakashima et al., 1999). 
First, we confirmed the mass spectrometry results by immunoprecipitation and Western blot 
analysis. We were able to identify both AAK1 and RALBP1 in MHC-I immune precipitates of 
both Atg5-/- and Atg5+/+ BM-DCs (Figure 3.10 A-B). However, only the association of AAK1 with 
MHC-I was significantly reduced in Atg5-/- BM-DCs, compared to their wild type counterparts 
(Figure 3.10 A). In good agreement, AAK1 association with MHC -I molecules was also reduced 
in Atg7 deficient BM-DCs (Figure 3.10 C).  
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Figure 3.10 AAK1 but not RALBP1 does not efficiently associate with MHC class I in the absence of LC3 lipidation. 
(A) AAK1 co-immunoprecipitation with MHC-I. Lysates of Atg5-/- and Atg5+/+ BM-DCs were used to 
immunoprecipitate MHC -I. On the left: representative immunoblot analysis showing the co-immunopreciptation (co-
IP) of AAK1 with MHC-I. On the right: quantification of 5 independent experiments. Co-immunoprecipitation intensity 
of AAK1 was normalized to MHC-I intensity. The AAK1 amount co-immunoprecipitated from the Atg5-/- samples (n=5 
mean= 76.8%, Standard error 5.9) and the Atg5+/+ samples (set to 100% as a reference) were compared. P value 
shown is from an unpaired non-parametric two tailed t test. (B) RALBP1 co-immunoprecipitation (co-IP) with MHC -
I: lysates of Atg5-/- and Atg5+/+ BM-DCs were used to immune precipitate MHC -I. On the left: representative 
immunoblot analysis showing the co-immunoprecipitation of RALBP1 with MHC-I. On the right: quantification of 3 
independent experiments. The co-immunoprecipitation intensity of RALBP1 was normalized to MHC-I. The amount 
of RALBP1 co-immunoprecipitated from the Atg5-/- samples and the Atg5+/+ samples (set to 100% as a reference) 
were compared and the indicated p value was determined by performing an unpaired non-parametric two tailed t 
test. (C) Lysates of Atg7-/- and Atg7+/+ BM-DCs were used to immunoprecipitate MHC-I. On the left: representative 
immunoblot analysis showing the co-immunopreciptation (co-IP) of AAK1 with MHC-I. On the right: quantification of 
3 independent experiments. Co-immunoprecipitation intensity of AAK1 was normalized to MHC-I intensity. The 
AAK1 amount co- immunoprecipitated from the Atg7-/- samples and the Atg7+/+ samples (set to 100% as a reference) 
were compared. P value shown is from an unpaired non-parametric two tailed t test of the non- normalized values.  
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RNA silencing of AAK1 stabilized MHC-I levels at the plasma membrane on both MEFs and 
BM-DCs (Figure 3.11), confirming its previously published role during receptor internalization 
(Ricotta, Conner et al. 2002).  
 
Figure 3.11 AAK1 silencing stabilized MHC class I on the cell surface 
Immunoblot for AAK1 on lysates from MEFs (A). One representative of 3 experiments is shown. (B) H2–Db surface 
expression levels on MEFs after AAK1 silencing with AAK1 specific siRNA as well as control siRNA. 4 experiments are 
summarized. P values were obtained from unpaired non-parametric two tailed t tests. 
Additionally, using the iLIR platform (Kalvari, Tsompanis et al. 2014); 
http://repeat.biol.ucy.ac.cy/iLIR/), we predicted two and one LIR (LC3-interacting region) 
motifs in the murine AAK1 and RALBP1 proteins, respectively (Scheme 3.2)  
 
Scheme 3.2 Predicted LIR motifs on AAK1 and RALBP1 
Representation of the domains of AAK1 (A) and RALBP1 (B). Purple lines represent the predicted LIR motifs. 
AAK1118-123: DVWEVL [score 18], AAK1914-919: DEFDPI [score 15], RALBP1318-323: LSWLIV [score 16]. 
Interestingly, the LIR sequences are conserved in the human AAK1 protein,  but not in human 
RALBP1. We validated the interactions of LC3 with AAK1 and RALBP1 by co-
immunoprecipitations. Indeed, we found that both, AAK1 (Figure 3.12A) and RALBP1 (Figure 
3.12B) could be co-immunoprecipiated with LC3, but this association did not seem to be 
influenced by the autophagy core machinery. These data suggest that LC3 lipidation via the 
autophagy core machinery is required to efficiently localize AAK1 to MHC-I molecules for 
optimal internalization and degradation. 
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Figure 3.12 AAK1 and RALBP1 association with LC3 is not influenced by autophagy machinery.  
(A) AAK1 co-immunoprecipitate with LC3. Lysates from Atg5-/- and Atg5+/+ BM-DCs were used to immune 
precipitate LC3. On the left: representative immunoblot analysis showing the co-immunoprecipitation (co-IP) of 
AAK1 with LC3. On the right: quantification of 3 independent experiments. The co-immunoprecipitation intensity of 
AAK1 was normalized to the total LC3 (I and II). The amount of AAK1 co- immunoprecipitated from the Atg5-/- 
samples (n=3) and the Atg5+/+ samples (set to 100% as a reference) were compared. Statistical analysis was 
performed with an unpaired non-parametric two tailed t test (ns, not significant). (B) RALBP1 co-
immunoprecipitates with LC3: lysates from Atg5-/- and Atg5+/+ BM-DCs were used to immune precipitate LC3. On the 
left: representative immunoblot analysis showing the co-immunoprecipitation (co-IP) of RALBP1 with LC3. On the 
right: quantification of 3 independent experiments. The co-immunoprecipitation intensity of RALBP1 was normalized 
to the total LC3 (I and II). The amount of RALBP1 co-immunoprecipitated in the Atg5-/- samples (n=3) and the Atg5+/+ 
samples (set to 100% as a reference) was compared and the indicated p value was determined by performing 
unpaired non-parametric two tailed t tests (ns, not significant).  
3.1.5 Enhanced antigen presentation on stabilized MHC class I molecules by 
autophagy deficient DCs in vitro 
In order to correlate the enhanced MHC-I expression on Atg5-/- DCs with better antigen 
presentation we tested the ability of DCs deficient in the autophagy machinery to restimulate 
anti-viral CD8+ T cell responses in vitro. We co-cultured influenza A virus (IAV) infected Atg5+/+ 
or Atg5-/- DCs with virus specific polyclonal memory T cells isolated from IAV infected wild-type 
animals. We found that infected Atg5-/- DCs were able to expand IAV specific memory CD8+ T 
cells more efficiently than Atg5+/+ DCs (Figure 3.13A-B). This applied to both influenza NP 
specific and overall CD8+ T cell populations. In contrast, IAV CD4+ T cell expansion was not 
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significantly different when stimulating with Atg5-/- or Atg5+/+ influenza infected DCs (Figure 
3.13C). 
 
Figure 3.13 Dendritic cells deficient in the molecular autophagy machinery have greater antigen presentation 
capacity to CD8+ T cells in vitro. 
(A) Influenza A virus infected or control Atg5-/- and Atg5+/+ splenic DCs were co-cultured with carboxyfluorescein 
succinimidyl ester (CFSE) labelled influenza virus-specific polyclonal memory T cells isolated from infected wild type 
animals. T cell proliferation was determined after 3 days of co-culture by flow cytometry. Percent of CFSE low cells of 
influenza NP1366-374/H2-Db tetramer positive (TM-NP, upper row) or total IAV specific CD8+ T cells (lower row) are 
indicated. One representative experiment out of 3 is shown. (B) Graphical analysis of T cell proliferation from 3 
independent experiments. P values were determined by unpaired non-parametric two tailed t tests. (C) Atg5-/- and 
Atg5+/+ DCs were co-cultured with CFSE labelled influenza specific polyclonal memory T cells isolated from wild type 
influenza virus infected mice. T cell proliferation was determined after 3 days of co-culture by flow cytometric 
analysis of the percentage of CFSE low CD4+ cells. Graph summarizing 3 independent experiments is shown. 
Statistical evaluation was performed with unpaired non-parametric two tailed t tests.  
Moreover, NP1366-374 peptide epitope pulsed Atg5-/- DCs also expanded polyclonal IAV 
specific memory T cells more efficiently than Atg5+/+ DCs (Figure 3.14). Blocking CD80 during 
this in vitro restimulation did not significantly affect T cell proliferation (Figure 3.14). 
Therefore, we concluded that autophagy deficiency causes enhanced antigen presentation of 
MHC-I restricted IAV derived epitopes by DCs.  
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Figure 3.14 Autophagy deficiency causes enhanced antigen presentation of MHC class I restricted IAV derived 
epitopes by dendritic cells. 
 (A) NP1366-374 pulsed Atg5-/- or Atg5+/+ splenic DCs were co-cultured with CFSE labelled influenza virus-specific 
polyclonal memory T cells isolated from infected wild type animals. T cell proliferation was determined after 3 days 
of co-culture with CD80 blocking antibody (+αCD80) or isotype control (+isotype) by flow cytometry. Percent of CFSE 
low cells of total CD8+ T cells are indicated. One representative experiment out of 3 is shown. (B) Summary of CD8+ T 
cell proliferation assay with 0.1 and 1 µM NP1366-374 peptide pulsed DCs as outlined in C values were determined by 
paired two tailed t tests. 
3.1.6 Elevated CD8+ T cell responses in DCs lacking LC3 lipidation protects from 
influenza A viral infection 
In order to validate our results in vivo, we infected Atg5-/- DC mice and their wild-type 
littermates (Atg5+/+ DC mice) with high dose (10 HAU) of IAV. The resulting CD8+ T cell 
responses specific for influenza antigens (NP1366-374, NP2311-325 and HA211-225) were markedly 
enhanced in mice lacking the autophagy machinery in DCs (Figure 3.15). Indeed, the 
magnitude of the specific CD8+ T cell response at day 11 post-infection was two to four times 
greater in Atg5-/- DC than in Atg5+/+ DC mice (Figure 3.15). In parallel, the specificity of the 
anti-viral CD8+ T cell responses was broader in Atg5-/- DC animals since at least two additional 
subdominant CD8+ T cell epitopes (HA211-225 and NP2311-325) were recognized at frequencies 
reaching 10% of CD8+ T cells apart from the dominant NP1366-374 epitope in the C57BL/6 mouse 
background (Figure 3.15). Accordingly, recognition of subdominant IAV epitopes reached 
levels of wild type dominant epitope recognition in Atg5-/- DC mice (Figure 3.15). 
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Figure 3.15 Broader specificity and enhanced magnitude of influenza specific CD8+ T cell responses in mice lacking 
Atg5 in their dendritic cells. 
(A) and (B) Levels of influenza virus specific CD8+ T cells in the lungs of wild-type mice (Atg5+/+ DC) and mice with 
Atg5 deficient DCs (Atg5-/- DC) were assessed 11 days after intranasal infection with 10 HA units of influenza virus 
strain A/PR8. Intracellular interferon-γ (IFN-γ) staining of CD8+ T cells after in vitro peptide re-stimulation with 3 
different viral epitopes (NP1366-374, NP2311-325 and HA211-225) was determined by flow cytometry. Background secretion 
was subtracted for every peptide, and determined for every mouse by using an irrelevant peptide control (Ny-ESO-
1157-170). (A) Representative FACS plots of PBS mock-infected or influenza infected mice. (B) Quantification of the 
specific anti-viral CD8+ T cell responses to the 3 different viral epitopes (NP1366-374, NP2311-325 and HA211-225) or their 
sum (Σ). Data are from three independent experiments, each with three to four mice per group. P values are from 
non-parametric unpaired two tailed t tests.  
Furthermore, we found that elevated CD8+ T cell responses correlated with protection from 
IAV induced disease. The infectious lung viral titres at day 8 were significantly reduced in Atg5-
/- DC mice (Figure 3.16A) indicating that the increased CD8+ T cell responses in the absence of 
the autophagy core machinery protected from morbidity during influenza A virus infection.  
 
Figure 3.16 Increased CD8+ T cell responses in the absence of the autophagy core machinery protected from 
morbidity during influenza A virus infection 
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 (A) Influenza lung viral titres were determined at day 8 post influenza infection, from supernatants of total lung 
homogenates from Atg5-/- or Atg5+/+ DC mice infected with 10 HAU of influenza A/PR8. Unpaired non-parametric two 
tailed t tests were used to obtain the indicated p values.  
The specific anti-viral CD4+ T cell responses and the influenza specific antibody titres were 
not significantly different in Atg5-/- DC animals compared to their wild- type littermates (Atg5+/+ 
DC) (Figures 3.17).  
 
Figure 3.17 IAV-specific CD4+T cells response and antibody titers are not affected in the absence of autophagy 
 (A) The specific antiviral CD4+ T cell response is not significantly different in Atg5-/- DC animals compared to 
Atg5+/+ DC animals. Influenza virus specific CD4+ T cells in the lungs of infected animals were assessed 11 days after 
intranasal infection with 10 HA units of influenza virus strain A/PR8. Intracellular interferon gamma (IFN-γ) staining 
of CD4+ T cells after in vitro peptide re-stimulation with the 2 different viral epitopes NP2311-325 (H2-Ab restricted) 
and HA211-225 (H2-Ab restricted) was determined by flow cytometry. Data are from three independent experiments 
with three to four mice per group. (B) Influenza A virus PR8 specific antibody titres were determined by serial 
dilution of serum collected at d11 post infection with 10 HA units. Data are from three independent experiments with 
three to four mice per group. 
In good agreement, MHC-I surface expression remained elevated on Atg5 deficient DCs and 
macrophages during IAV infection (Figure 3.18), while with the exception of CD80 co-
stimulatory molecules were unchanged (Figure 3.18). Thus, while the protective CD8+ T cell 
response is selectively enhanced in infected mice with Atg5 deficient DCs, CD4+ T cell and 
antibody responses are unaffected. 
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Figure 3.18 During IAV infection MHC class I levels remain elevated in absence of Atg5 
 (A) MHC -I surface levels on the indicated Atg5+/+ and Atg5-/- lung DC and macrophage populations at day 4 of IAV 
infection. Data are from 3 independent experiments with 3 to 4 mice per group. P values are derived from unpaired 
non-parametric two tailed t tests. (B) Surface levels of the indicated co-stimulatory molecules on Atg5+/+ and Atg5-/- 
lung DC and macrophage populations at day 4 of IAV infection. P values are derived from unpaired non-parametric 
two tailed t tests. 
3.1.7 Cytokine production and early viral titres in Influenza A infected mice with 
DCs that lack components of the autophagy machinery 
In the initial stage of influenza infection, innate immunity and cytokine secretion play an 
important role in controlling the replication rate of the virus and the following inflammation 
and adaptive immune response. In order to exclude that changes in early innate immune 
control would allow influenza A virus to replicate to higher viral titres resulting in elevated IAV 
specific CD8+ T cell responses in Atg5-/- DC mice, we analysed cytokine production and IAV 
titres on day 3 after infection. Cytokine secretion in response to infection was similar for IL-6 
and IFN-γ in Atg5-/- DC mice (Figures 3.19A-B). IL-1β, however, was increased (Figure 3.19C), 
but these elevated IL-1β levels were not able to control IAV infection early on, as demonstrated 
by similar viral titres between wild-type and knock-out mice on day 3 after infection (Figure 
3.19D). Therefore, changes in innate immune control are unlikely to account for the elevated 
CD8+ T cell responses and improved immune control in Atg5-/- DC mice. 
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Figure 3.19 Innate immune protection to influenza A virus is not different in Atg5-/- DC mice at day 3 post infection. 
(A) Atg5-/- and Atg5+/+ DC mice were infected with 10 HA units for 3 days. (A) and (B) IL-6, IFN-γ and IL-1β levels 
(C) were measured by ELISA assays in lung homogenates. (D) Viral RNA was quantified in lung homogenates at day 3 
post infection: Graph representing delta CT values of quantitative RT-PCR for 3 viral segments (M, HA and NA) are 
shown. Results are from 3 independent experiments with at least 3 mice per group. In each experiment PBS treated 
mice were used as negative controls. 
3.1.8 Elevated CD8+ T cell responses to two LCMV epitopes during infection of 
mice with DCs deficient in the autophagy machinery 
In order to address the role of elevated MHC -I expression on Atg5-/- DCs for better CD8+ T 
cell priming in a different infectious model, we tested acute LCMV infection. Atg5-/- DC animals 
and their wild-type littermates (Atg5+/+ DC) were infected intravenously with the wild type 
LCMV Armstrong strain at a dose of 104 plaque forming unit (PFU). The specific CD8+ T cell 
response to two viral epitopes was monitored at day 6 and day 11 post infection. We did not 
find a difference in the anti-viral CD8+ T cell response at day 6 between the two groups (data 
not shown). However at day 11, the anti-viral CD8+ T cell response was significantly elevated in 
Atg5-/- DC animals (Figure 3.20). The percentages of MHC-I tetramer positive cells that are 
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specific to two viral LCMV epitopes, the immunodominant H2-Db-NP396 and the subdominant 
H2-Kb-GP34 epitope, were up to two-fold higher in Atg5-/- DC animals (Figure 3.20). These data 
suggest that stabilized MHC -I levels on autophagy machinery deficient DCs contribute to 
elevated priming of anti-viral CD8+ T cell responses in vivo. 
 
Figure 3.20 Enhanced LCMV specific CD8+T cell responses in mice lacking the autophagy machinery in their DCs. 
Atg5-/- DC animals and their wild-type littermates (Atg5+/+ DC) were infected intravenously with the wild type 
LCMV Armstrong strain at a dose of 104 PFU. The specific CD8+ T cell response to two viral epitopes was monitored in 
the blood, at day 11 post infection, using specific MHC-I tetramers. Data are from three independent experiments, 
each with three to four mice per group. (A) Percentage of MHC-I tetramer positive cells of CD8+ T cells specific for the 
H2-Db restricted NP396-404 (Db-NP396, upper row) or the H2-Kb restricted GP34-43 (Kb-GP34, lower row) epitope in the 
blood of Atg5+/+ or Atg5-/- DC mice. (B) Combined data as in (A) for all three experiments. Paired non-parametric two 
tailed t tests were performed on the mean values from each experiment to obtain the indicated p values. 
Taking together these findings clearly demonstrate that the molecular machinery of 
autophagy not only serves for transporting cytoplasmic constituents for lysosomal degradation, 
but that it also assists in the process of MHC-I internalization and in their absence more 
stimulatory MHC-I molecules are present on the surface of DCs to elicit elevated CD8+ T cell 
response 
Further studies will need to address how one might selectively regulate these different 
autophagy functions on MHC-I-restricted antigen presentation for therapeutic interventions to 
boost adaptive immunity. 
 
 53 
 
Part II- Autophagy in MHC class I antigen 
processing 
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3.2.1 EBNA1 targeting to autophagosomes increases MHC class I antigen 
presentation to CD8+ T cells mainly in TAP deficient cells  
The autophagy machinery restricts MHC-I presentation by attenuating MHC-I surface 
expression levels. However, as it is a catabolic process by nature, it is also tempting to speculate 
that autophagy has a role in antigen processing for MHC-I presentation, especially under 
conditions of classical MHC-I pathway impairment, for example during viral infection such as by 
herpes viruses. The involvement of autophagy in unconventional MHC-I antigen presentation 
were addressed by investigating the MHC-I presentation of intracellular Epstein Barr virus 
(EBV) antigens, such as the latency protein EBNA1 in lymphoblastoid cells (LCLs), namely HLA-
B*3501 transgenic TAP-deficient (T2.B35) and TAP-sufficient (T1.B35) B cells. Both of these 
cell lines are latently infected with EBV but T2 cells express at their surface lower levels of 
MHC-I molecules in comparison to T1 since the lack of TAP results in inefficient formation of 
peptide-MHC-I complexes due to poor availability in the ER of high affinity peptides (Figure 
3.21A). Moreover, in order to investigate to what extent epitope display could be enhanced by 
increasing EBNA1 expression and subcellular targeting, T2.B35 and their HLA-B*3501-
expressing parental cells T1.B35 have been transduced with GFP-tagged lentiviral vectors 
expressing different constructs of the immunogenic C-terminus of the EBV latency protein 
EBNA1 (EBNA1400-641), defective for the glycine-alanine repeats (GAr) that are responsible for 
the inhibition of EBNA1 presentation on MHC-I molecules via compromising EBNA1 mRNA 
translation as well as its own proteasome degradation (Yin, Manoury et al. 2003; Daskalogianni, 
Apcher et al. 2008). These include GAr-depleted EBNA1 (E1Δ), Invariant chain-EBNA1 (Ii-E1Δ), 
which would allow a more efficient delivery into the MHC-II loading compartment, and EBNA1-
LC3 (E1Δ-LC3) to target autophagosomes (Figure 3.21B). 
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Figure 3.21 Characterization of the cellular model used for the study 
(A) Surface expression of MHC-I molecules on untransfected wild type (T1) and TAP-deficient (T2) 
lymphoblastoid cell lines (LCLs). Cells were stained with FITC-labelled anti-MHC-I (w6/32) and analysed by FACS. 
Graph summarize the mean fuorescence intensity (MFI) and SEM. (B) LCLs were lentiviral transduced with different 
EBNA1 constructs (GAr-depleted EBNA1 (E1Δ), EBNA1-LC3 (E1Δ-LC3), and Invariant chain-EBNA1 (Ii-E1Δ)) and 
their protein content was analysed by Western blot. Numbers below bands indicate the ratio of normalised intensity 
of the EBNA1 construct band compared to actin. 
The specific CD8+ T cell recognition of an EBNA1 epitope (EBNA1407–417) was then evaluated 
by IFN-γ production after overnight coculture of TAP-sufficient and –deficient HLA-B*3501 
cells with an EBNA1407-417 specific CD8+T cell clone. Preliminary data surprisingly show that 
overall T2.B35 cells were slightly better than T1.B35 in triggering IFN-γ release (Figure 
3.21A). More interestingly, epitope presentation increased with elevated antigen expression, 
especially when EBNA1 was fused with LC3 and targeted to autophagosomes in T2.B35 cells, 
providing the first promising evidence that in this model, for this epitope, autophagy could be 
involved in antigen presentation on MHC-I molecules, preferentially in the absence of TAP 
(Figure 3.22A). Interestingly, fusion with Ii also led to an increased antigen presentation by 
cells lacking in TAP expression, suggesting a targeting of MHC-I to the endolysosomal 
compartment for loading in conditions of defective MHC-I pathway (Figure 3.22A). 
3.2.2 Effects of autophagy manipulation on MHC class I presentation of EBNA1  
To evaluate the involvement of autophagy in MHC-I presentation of EBNA1 epitopes, 
changes in EBV antigen presentation were evaluated after pharmacological inhibition of 
autophagy. Untransfected and EBNA1 constructs transfected T1.B35 and T2.B35 cells were 
exposed to the lysosomotropic agent chloroquine for 6 h prior overnight coculture with the 
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EBNA1-specific CD8+T cell clones (Figure 3.22B). Surprisingly, the overall effect of CQ was to 
increase IFN-γ production in response of antigenic presentation provided by all cells treated 
with CQ in comparison to the untreated ones (Figure 3.22C), with a more pronounced effect on 
T2.B35 cells. Indeed, upon CQ treatment the difference between T1.B35 and T2.B35 in their 
ability to present EBNA1407-417 became more pronounced (Figure 3.22B). Similarly, targeting of 
EBNA1 to autophagosomes and to MIIC in the presence of CQ results in a statistically significant 
increase in IFN-γ production in comparison to untransfected cells (Figure 3.22B).  
 
Figure 3.22 Increased EBNA1 MHC class I-restricted presentation in absence of TAP  
Untransfected and EBNA1 constructs (GAr-depleted EBNA1 (E1Δ), EBNA1-LC3 (E1Δ-LC3), and Invariant chain-
EBNA1 (Ii-E1Δ)) transfected HLA-B*3501 TAP-sufficient and deficient cells (T1.B35 and T2.B35, respectively) were 
coculture with EBNA1407–417-specific CD8+ T cell clones (ratio LCLs:T cells 10:1) and IFN-γ production was quantified 
by ELISA assays. (A) untreated cells; (B) LCLs were treated with chloroquine (CQ) for 6 hours before overnight 
coculture with CD8+T cell clones; (C) Comparison of IFN-γ production by CD8+T cells clones after coculture with 
either untreated and CQ treated LCLs. Graphs summarise data from 5 independent experiments. Bars indicate mean 
+/- SEM. If not indicate data are not statistically significant. 
These preliminary data suggest that CQ, by blocking the final step of autophagy, such as the 
acidification of the autophagosomes, might redirect the fusion of autophagosomes with 
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endosomal compartment rich in MHC-I molecules that are available for loading and recycling to 
the cell surface. Alternatively, CQ also prevents internalized MHC-I degradation and allows it to 
also more efficiently gain access to vesicular loading compartments. Moreover, CQ-dependent 
enhancement of LC3 lipidation might result in a higher contribution of autophagy to antigen 
presentation. Studies on the effects of autophagy manipulation via different pharmacological 
agents or via specific silencing are ongoing. 
3.3.3 Characterization of autophagy in antigen presentation in TAP deficient 
cells 
Subsequently, the possible role of autophagy in intracellular antigen processing was studied 
in more detail by immunofluorescence. Analysis of MHC-I and LC3 localization in both HLA-
B*3501 wild type and TAP-negative cells by confocal microscopy revealed that MHC-I 
molecules reside within LC3-positive compartments preferentially in the absence of TAP, 
strengthening the hypothesis mentioned earlier that autophagosomes could fuse with MHC 
loading endosomal compartment. Accordingly, the supply of more antigens seemed to result in 
a further increase of LC3/MHC-I colocalization, when EBNA1 is targeted to LC3+ or Ii+ 
compartments (Figure 3.23).  
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Figure 3.23 Immune fluorescence staining and colocalization analysis for MHC class I and LC3 
LCLs were cytospun onto slides, fixed in 4% paraformaldehyde 20 min at RT and then assessed for the 
localisation of either MHC-I with LC3 (A) by co-staining with the pan MHC-I w6/32 and anti-LC3 antibodies 
followed by AlexaFluor-488-labelled goat anti-mouse and AlexaFluor-555 goat anti-rabbit antisera, respectively. (B) 
Pearson’s coefficient for MHC-I and LC3 colocalization. Unpaired non-parametric two tailed t tests were performed 
to obtain the indicated p values. 
3.3.4 Characterization of MHC-I source and MHC-I loading compartment in 
absence of TAP 
As in absence of TAP it is unlikely that the MHC-I loading would take place within the ER, we 
tried to investigate in which compartment the alternative MHC-I loading could take place and 
which is the source of MHC-I molecules for this compartment. In order to address where the 
MHC-I molecules come from, we stained wild type and TAP-deficient HLA-B*3501 cells for 
AAK1, a kinase shown to facilitate MHC-I internalization upon LC3 lipidation in mouse DCs (See 
Part I). Accordingly, preliminary data show that in TAP-negative cells, AAK1 colocalizes to a 
higher extent with MHC-I molecules in comparison to T1.B35 cells (Figure 3.24 A-B), 
suggesting that the upregulation of AAK1 mediated internalization could be needed to supply 
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MHC-I molecules that can be loaded in the absence of TAP. Studies investigating the 
contribution of AAK1-mediated internalization in providing the MHC-I pool for peptide loading 
in the absence of TAP are ongoing. 
Furthermore, in order to characterize the MHC -I reservoir that is preferentially used for 
autophagic antigen processing towards CD8+ T cell stimulation, T2.B35 and T1.B35 cells were 
stained for the recycling endosome-specific marker RAB11. MHC -I molecules colocalize with 
RAB11 preferentially in the absence of TAP (Figure 3.24C-D). This suggests that in TAP-
deficient cells, large MHC-I pools might be contained within endosomal recycling compartments 
fed by endocytosis mediated by AAK1 and the autophagy machinery. Staining for other 
compartment-specific markers, such as SNAREs and Rabs are ongoing. 
 
Figure 3.24 Immune fluorescence staining and colocalization analysis for MHC class I with AAK1 and RAB11 
LCLs were cytospun onto slides, fixed in 4% paraformaldehyde 20 min at RT and then asses sed for the 
localisation of MHC-I with either AAK1 (A) or RAB11 (C) by co-staining with w6/32 and anti-AAK1 or anti-RAB11 
antibodies followed by AlexaFluor-488-labelled goat anti-mouse and AlexaFluor-555 goat anti-rabbit antisera, 
respectively. Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI). Image acquisition was performed 
using a confocal laser scanning microscope. Image deconvolution and colocalisation analysis was performed with 
ImageJ software. The presented data summarize one experiment. (B) Colocalization coefficient for AAK1 and MHC-I; 
(D) Colocalization coefficient for MHC-I and RAB11. Unpaired non-parametric two tailed t tests were performed to 
obtain the indicated p values. 
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Thus, the presented preliminary data suggest that autophagy might play a role in antigen 
processing when the classical pathway is defective, as in the absence of TAP. CD8+T cell 
activation could be regulated upon inhibition of autophagic cargo degradation by lysosomes. On 
the other hand autophagy might to also supply the endosomal antigen-loading compartment 
with MHC-I molecules via its interaction with AAK1. These MHC-I molecules might be 
internalized from the plasma membrane to be loaded in a TAP-independent manner. 
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Our studies describe a dual role of autophagy in MHC-I-restricted antigen presentation (Figure 
4.1). On one hand, we showed that in murine CD11c-expressing cells lipidated LC3 recruits the 
internalization machinery to MHC-I molecules. In the absence of this recruitment, MHC-I gets 
stabilized on the surface of myeloid antigen presenting cells resulting in elevated CD8+ T cell 
responses during IAV and LCMV infections. On the other hand, preliminary data on EBV- 
immortalized B cells strongly suggest that the autophagy pathway participates in antigen 
processing for MHC-I of the endogenous EBNA1 in the absence of TAP. 
4.1 Autophagy-mediated internalization of classical MHC class I molecules in 
comparison to MHC class II and non-classical MHC class I molecules 
Intracellular trafficking routes of MHC-I molecules have not been clearly defined yet, because 
they vary according to cell type, to the specific MHC allele investigated, to the conformation and 
the type of the MHC-I molecule. While in non-professional APCs MHC-I internalization seems to 
follow clathrin-independent endocytosis mediated by Arf6 (Naslavsky, Weigert et al. 2004), in 
mouse DCs it was shown that the MHC-I cytoplasmic tail contains a cryptic tyrosine-based motif 
for clathrin-mediate endocytosis responsible for internalization and targeting of MHC-I to 
endosomal compartments in the context of cross-presentation of exogenous antigens and anti-
viral cytotoxic T cell priming (Lizee, Basha et al. 2003; Basha, Lizee et al. 2008). Upon Arf6 
internalization, cargo-containing vesicles fuse with early endosome compartment and their 
subsequent trafficking requires Rab22a (Cebrian, Croce et al. 2016). Interestingly, this pathway 
intersects with the clathrin-mediated endocytosis pathway as Rab11, the classical marker 
associated with the tubular structures of endosomal recycling compartments involved in clathrin-
dependent cargo recycling, such as transferrin receptor, is involved in the Arf6-dependent 
pathway (Weigert, Yeung et al. 2004). It is important to note that the Arf6 pathway together with 
the associated proteins have not been investigated yet in professional antigen presenting cells 
such as DCs. Moreover, a fairly recent study described that in mouse DCs a MHC-I pool exists that 
resides in Rab11-positive, but Arf6-negative endolysosomal compartment (Nair-Gupta, Baccarini 
et al. 2014), strengthening the concept that MHC-I molecules follow different intracellular 
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pathways based on the cell type. On the other side, the mentioned study is in line with the reported 
role on the recognition of the tyrosine motif as important element in DCs to target internalized 
MHC-I molecules to cross-presentation compartments. The tyrosine motif is implied in clathrin-
mediated endocytosis as it is specifically recognized by adaptor proteins, such as AP-2 that upon 
phosphorylation by adaptor-associated kinase (AAK1), increases its affinity for the tyrosine motif 
within the target molecule (Honing, Ricotta et al. 2005), resulting in the invagination of the plasma 
membrane and formation of clathrin-coated vesicles. However, there is a caveat. In spite of the 
data showing the importance of the tyrosine motif in MHC-I trafficking, the involvement of clathrin 
in this process is just an assumption as no study has provided a formal demonstration so far. 
However, the involvement of AAK1, a kinase involved in clathrin-mediated endocytosis, in MHC-I 
internalization reported in the present thesis further supports a role of clathrin-mediated 
endocytosis for MHC-I. Similar considerations concern the CD1 family of MHC-I-like protein (CD1a, 
CD1b, CD1c, CD1d and CD1e), which present lipid antigens to T cells. CD1a molecules lack the 
tyrosine motif in their cytoplasmic tail and in HeLa cells have been shown to follow clathrin-
independent internalization and Arf6- and Rab22a-dependent trafficking (Barral, Cavallari et al. 
2008; Cebrian, Croce et al. 2016). On the other hand, CD1b, CD1c and CD1d can bind AP-2 via their 
tyrosine sorting motif and CD1b and CD1c have been shown to localize in clathrin-coated vesicles 
(Sugita, Jackman et al. 1996; Briken, Jackman et al. 2002; Lawton, Prigozy et al. 2005). Moreover, 
like for MHC-I molecules, the sorting motif has been shown to be indispensable for the trafficking 
into endolysosomal compartments (Sugita, Jackman et al. 1996). MHC-II molecules trafficking and 
internalization also follows multiple pathways. In the case of MHC-II a distinction has to be made 
according to endocytosis in association with invariant chain (Ii), which stabilized MHC-II in the 
absence of peptide, or as the peptide-loaded mature MHC-II form. While the former enters the 
endocytic pathway by clathrin-mediated endocytosis dependent on dileucine-based sorting signals 
in the cytosolic domain of Ii (Lotteau, Teyton et al. 1990), the internalization of peptide-MHC-II 
complexes seems to be dependent on Arf6 (Walseng, Bakke et al. 2008). 
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Here, my studies have provided evidence that in murine CD11c-expressing cells, internalization 
of classical MHC-I molecules is mediated by the recruitment of the clathrin-mediated endocytosis 
machinery, specifically the adaptor protein kinase AAK1, by LC3 lipidation. Interestingly, AAK1 
carries two putative LIR motifs that might explain the association with LC3. Of note, the adaptor 
protein 2 (AP2), substrate of AAK1, was not found enriched in MHC-I immunoprecipates of wild 
type cells suggesting that, in our system, AAK1 likely supports the previously described AP2-
independent, but clathrin-dependent endocytosis pathways (Henderson and Conner 2007; Gupta-
Rossi, Ortica et al. 2011). The model depicted in Figure 4.1D is inferred from the data presented in 
my PhD thesis and from published literature. The mechanism proposed considers that AAK1 
associates with cytosolic LC3. When LC3 gets lipidated at the plasma membrane (Fujita, Itoh et al. 
2008), AAK1 comes in proximity of MHC-I molecules resulting in their internalization by an AP-2-
independent process and presumably in LC3-coated vesicles. In absence of Atg5, MHC-I molecules 
get stabilized at the cell surface, resulting in an enhanced CD8+T cell response during IAV and 
acute LCMV infections, demonstrating a functional role of the autophagy mediated MHC-I 
endocytosis. Additionally, preliminary data suggest that AAK1 plays a role in MHC-I internalization 
in EBV-infected B cells mainly during impairment of the classical MHC-I pathway. Similarly, a 
recent study found that internalization of the MHC-I-like molecule CD1d, which, as mentioned 
above, similar to classical MHC-I contains a tyrosine-based motif in its cytoplasmic tail, follows a 
clathrin-dependent endocytosis mediated by AP2 that is regulated by autophagy proteins. In 
absence of Atg5, CD11c-expressing cells, display higher levels of CD1d at their surface, linked to a 
prolonged glycolipid presentation on CD1d, which in turn enhanced activation of a subset of T 
cells known as invariant natural killer T (NKT) cells and improved the clearance of Sphingomonas 
paucimobilis infection (Keller, Loi et al. 2017). In line with these studies, the Alzheimer precursor 
protein has been shown to be internalized by a LC3-dependent mechanism based on the presence 
of a LIR motif within AP-2 sequence (Tian, Chang et al. 2013). Moreover, clathrin itself has been 
shown to contain a LIR motif and to contribute to autophagosome formation (Ravikumar, Moreau 
et al. 2010; Mari, Tooze et al. 2011). Interestingly, a possible role of autophagy in membrane 
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receptor trafficking, could have been envisioned already more than 25 years ago when Reid and 
Watts showed that primaquine, now being shown to also inhibit  autophagy (Goodall, Wang et al. 
2014),  and previously known to inhibit transferrin receptor recycling, transiently blocks the 
recycling of MHC-I within cells (Reid and Watts 1990). Thus, the autophagy machinery seems to 
affect different clathrin-dependent internalization and degradation steps of surface receptors, 
including MHC-I endocytosis. However, it cannot be excluded that, in our model, in addition to 
MHC-I stabilization, trafficking of other molecules might be regulated by autophagy, and thereby 
contribute to enhanced CD8+T cell responses after viral infections in the absence of Atgs. Indeed, 
the elevated CD80 surface expression on some subsets of DCs and the increased IL-1β production 
early during influenza A virus infection could contribute. Along this line, it has been reported using 
other models that absence of autophagy proteins resulted in a hyper-reactivity of CD8+ T cell 
responses to allogeneic APCs (Hubbard-Lucey, Shono et al. 2014) and to colorectal tumour cells 
(Levy, Cacheux et al. 2015). 
From the data shown in this thesis, it is also possible to speculate that as LC3 gets lipidated, 
AAK1 is recruited to the MHC-I at the cell surface not only for internalization but also for possible 
degradation by an ubiquitin, clathrin- and dynamin-dependent internalization pathway. Indeed, 
besides endosomal targeting mediated by the tyrosine-based motif, the cytoplasmic domain of 
MHC-I molecules contains two or three conserved lysine residues (Duncan, Piper et al. 2006). 
Lysines are targets for ubiquitination that can also induce clathrin-dependent endocytosis. The 
ubiquitylation of the cytoplasmic domains on MHC-I targets them to the late endosome pathway 
for degradation. Studies on immune evasion by herpes simplex viruses have provided a potential 
mechanism for this degradation, leading to the identification of membrane-associated RING-CH 
(MARCH) E3-ubiquitin ligases, human homologs of RING-CH viral proteins K3 and K5 of KSHV 
(Bartee, Mansouri et al. 2004). Indeed, MARCH IV and IX are related in sequence and when 
overexpressed, each one causes ubiquitylation and downregulation of MHC-I, CD4 and ICAM-1 
(Nathan and Lehner 2009). Recently, it has been shown that MARCH IX overexpression prevents 
surface accumulation of MHC-I in monocyte-derived DCs, as well as the MHC-I-like molecule CD1a, 
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through the ubiquitination of lysine residues present in the cytoplasmic tails of these 
transmembrane proteins (De Angelis Rigotti, De Gassart et al. 2017). Similarly to MHC-I, in 
immature DCs, a role for ubiquitylation in mitigating the surface expression of peptide-MHC-II 
complex has been described (Cho and Roche 2013). Specifically, peptide-MHC-II complexes are 
ubiquitylated by the E3 ubiquitin ligase MARCH I in B cells and DCs, enhancing their endocytosis 
(Matsuki, Ohmura-Hoshino et al. 2007).  
Thus, autophagy proteins seem to participate in clathrin-dependent endocytosis pathways for 
the internalization and, possibly, degradation of both classical and non-classical MHC-I molecules. 
4.2 Autophagy in antigen processing for MHC class I versus MHC class II 
Autophagy mediates antigen processing for MHC-II presentation via autophagy and LAP. 
Indeed, both autophagosomes and LAPosomes (LC3-coated single membrane vesicles formed 
upon LAP) supply either endogenous or exogenous antigens, respectively, to endosomal antigen-
loading compartment for MHC-II presentation. Similarly, however still controversial, classical 
MHC-I restricted antigen presentation and cross-presentation seems to be regulated by autophagy 
(Figure 4.1). With respect to MHC-I presentation of endogenous antigen, it has been shown that 
antigens targeting to autophagosomes by fusion constructs with LC3 did not result in an increased 
MHC -I presentation (Schmid, Pypaert et al. 2007) and autophagy seems to even restrict MHC-I 
antigen presentation of DRiPs (Wenger, Terawaki et al. 2012). However, under conditions of 
inhibition of the classical MHC-I antigen-processing pathway such as during herpesvirus infection, 
alternative MHC-I pathways, such as autophagy, exist and circumvent viral immune escape 
mechanism. Indeed, late in herpes simplex virus 1 and human cytomegalovirus infection, it was 
reported that autophagy can deliver endogenous antigens for MHC-I presentation (English, 
Chemali et al. 2009; Tey and Khanna 2012). Accordingly in my studies in TAP-deficient EBV 
transformed B cells, fusion of LC3 to EBNA1 defective for proteasome inhibiting glycine-alanine 
repeats, results in an increased MHC-I presentation confirming the suggested role of autophagy 
during herpes virus infection. Interestingly, in the absence of TAP, fusion constructs with Ii seem 
also increase endogenous EBV antigen presentation on MHC-I, likely targeting antigen to the 
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endosomal compartment where the MHC-I loading takes place. It is then tempting to speculate that 
similarly to the autophagy-dependent MHC-II loading pathway, autophagosomes can fuse with 
endosomal-loading compartments, thereby providing endogenous antigens for MHC-I 
presentation. Additionally, blocking the acidification of autophagolysosomes by chloroquine 
treatment resulted in an increase of IFN- release by EBNA1-specific CD8+T cell clones suggesting 
that the inhibition of the autophagic flux might redirect the resulting accumulated 
autophagosomes to fuse with endosomal compartments eventually rich in MHC-I molecules that 
are available to be loaded and recycled back to the cell surface. However, it might be also possible 
that chloroquine enhances an LAP-like pathway and increases LC3 lipidation on endolysosomal 
compartments, possibly by preventing their degradation (Florey, Gammoh et al. 2015) could result 
in a higher contribution of the autophagy machinery to supply internalized MHC-I to endosomal-
loading compartments. Moreover, it was shown that in TAP-deficient cells, exogenous vaccinia 
virus antigen follows a TAP-independent MHC-I antigen-presentation pathway that requires 
autophagy for CD8+T cell activation (Johnstone, Ramos et al. 2012). Nevertheless, the contribution 
of autophagy to cross-presentation is still controversial. While some studies found that Atg 
deficiency in antigen presenting cells did not affect exogenous antigen cross- presentation to CD8+ 
T cells (Lee, Mattei et al. 2010), others have shown that the autophagy machinery enhances (Fiegl, 
Kagebein et al. 2013; Mintern, Macri et al. 2015) or inhibits (Baghdadi, Yoneda et al. 2013; 
Hubbard-Lucey, Shono et al. 2014) cross-presentation. Moreover, it has been suggested that the 
autophagy machinery supplies antigens for cross-presentation by helping the packaging of 
antigens to be transferred from cell to cell (Li, Wang et al. 2008; Uhl, Kepp et al. 2009).  
Thus, autophagy proteins participate in MHC-II and balance MHC-I antigen presentation. 
Indeed, CD8+T cell response could be restricted in normal physiological conditions while during 
impairment of the classical MHC-I pathway, the autophagy machinery could participate in antigen 
processing for presentation to CD8+ T cells. 
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Figure 4.1 Autophagy in MHC-I and MHC-II presentation. 
(A) Macroutophagy involves the engulfment of cytoplasmic material and the formation of autophagosomes, which 
then can fuse with MHC-II-containing compartments. Antigenic peptides are then loaded onto MHC -II molecules, which 
can be delivered to the plasma membrane for CD4+ T cell stimulation. Some evidence suggests that autophagy could also 
supply antigens to a similar compartment for vacuolar MHC-I loading (B) During LC3-associated phagocytosis (LAP) 
phagosomes are decorated with LC3. After LC3 cleavage from their membrane, phagosomes fuse with MHC -II loading 
compartments. Their cargo is degraded and fragments are loaded onto MHC-II molecules. LAP facilitates lysosome-
phagosome fusion or prolonged antigen processing for presentation by MHC-II in a species–specific manner. Similarly, 
LAP could also be involved in MHC-I cross-presentation (C) Macroautophagy degrades intracellular proteins, which 
otherwise might serve as substrates for proteasomes. The resulting proteasome products give rise to MHC -I ligands 
after import into the ER by the canonical MHC-I antigen processing pathway. (D) In addition, autophagy attenuates 
MHC-I-restricted presentation by recruiting the internalization machinery to the MHC-I molecules at the cell surface. 
Here, AAK1 associates with, presumably membrane-bound, LC3-II and triggers MHC-I internalization resulting in a 
diminished stimulation of CD8+ T cells. Moreover, MHC-I that is internalized by such LAP-like processes could serve as a 
source for vacuolar MHC-I loading.  
4.3 Peptide loading compartment in absence of TAP in comparison to cross-
presentation 
As mentioned, alternative pathways for MHC-I presentation exist and they are particularly 
important when the classical pathway is impaired for example during viral infections. These 
pathways are under intense investigation and some questions still need to be addressed. Since 
during cross-presentation, loading and MHC-I source do not follow the classical pathway, it can be 
hypothesized that common compartments/processes exist that support both alternative pathways 
of endogenous MHC-I antigen loading and cross-presentation. The characterization of such MHC-I 
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loading compartments and the supply to them as well as characteristics of MHC-I molecules in 
them are still important open questions.  
Evidences from cross-presentation studies have demonstrated that 20% of the protein in early 
phagosomes in DCs (Campbell-Valois, Trost et al. 2012) depends on functional TAP and PLC 
recruitment from the ERGIC via the SNARE Sec22b (Ackerman, Kyritsis et al. 2003; Guermonprez, 
Saveanu et al. 2003; Houde, Bertholet et al. 2003; Cebrian, Visentin et al. 2011). With the same 
mechanism, it is likely that also MHC-I can be recruited from the ERGIC to the phagosome where 
they can be loaded. Alternatively, newly synthetized MHC-I could reach the phagosome after 
exiting the ER in association with Ii (Basha, Omilusik et al. 2012). Nevertheless, strong evidence 
supporting the use of ER-derived MHC-I as a source for the endosomal-loading compartment is 
lacking and the most accepted hypothesis suggests that the primary source is the recycled MHC-I 
from the cell surface. Indeed, in mouse DCs clathrin-mediated endocytosis has been shown to 
supply MHC-I molecules for cross-presentation (Reid and Watts 1990; Lizee, Basha et al. 2003; 
Basha, Omilusik et al. 2012). We showed that in mouse CD11c-expressing cells, the impairment of 
autophagy-dependent internalization of MHC-I via an unconventional use of the autophagy 
machinery in AAK1-dependent endocytosis depletes the intracellular vesicular pool of MHC-I. 
Interestingly, LC3-PE‒coated vesicles have been reported to possibly fuse with vesicular MHC-I 
loading compartments for cross-presentation of antigens from respiratory syncytial virus, HIV, 
Chlamydia bacterial species and Aspergillus mold species (Blanchet, Moris et al. 2010; De Luca, 
Iannitti et al. 2012; Johnstone, Ramos et al. 2012; Fiegl, Kagebein et al. 2013). Additionally, our 
preliminary data indicate that MHC-I molecules traffic into RAB11+ vesicles, thereby suggesting 
that Atg-dependent internalization pathways shuttle MHC-I from the cell surface to the recently 
identified vesicular MHC-I storage compartment that is marked by Rab11a, VAMP3 and VAMP8 
(Nair-Gupta, Baccarini et al. 2014), which has been demonstrated to supply MHC-I molecules 
during cross-presentation. 
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Thus, in absence of TAP, the autophagy machinery might play a dual role in vesicular loading of 
MHC-I by delivering antigen and supplying MHC-I molecules to the endosomal-loading 
compartment. 
Taking together, data reported in the present PhD thesis provide evidence that autophagy is not 
simply a catabolic process but it also influences antigen processing, vesicular MHC-I loading and 
trafficking, that results in the regulation of T cell immunity (Figure 4.1). Further studies will need 
to be conducted in order to understand how one might selectively regulate these different Atgs 
functions during MHC-restricted antigen presentation for therapeutic interventions to boost 
adaptive immunity in response to several virus-associated antigens, especially when the classical 
MHC-I antigen presentation route is compromised. 
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5.1 Peptides, Chemical, Cytokines and Antibodies 
Peptides NP366-374 (NP1), HA211-225, NP311-325 (NP2), and NY-ESO-1157-170 were synthesized by GL 
Biochem (Shanghai) at a purity >90 %. EBNA1407-417 peptide (HPV peptide) was synthesized by 
peptides&elephants. CarboxyFluorescein Succinimidyl Ester (CFSE) was used at 0.5 mM and was 
from Molecular Probes. Chloroquine was used at concentration of 25 µM and 50 µM, at the 
indicated time points and purchased from Sigma. Mouse recombinant GM-CSF (BioLegend) and IL-
2 (R&D) were used at 20 ng/ml and 40 IU/ml respectively.  
Antibodies used are listed in Table 5.1a and b. 
Antibody Clone Conjugation Company Assay 
Anti-mouse MHC-II M5/114.15.2 APC Biolegend FC 
Anti-mouse CD11c N418 PE-Cy7 Biolegend FC 
Anti-mouse CD4 GK1.5 PB Biolegend FC 
Anti-mouse CD8 53-6.7 APC Biolegend FC 
Anti-mouse CD11b M1/70 APC-Cy7 Biolegend FC 
Anti-F4/80 BM8 Alexa 700 Biolegend FC 
Anti-mouse Ly6C HK1.4 PerCP/Cy5.5 Biolegend FC 
Anti-mouse CD103 2E7 APC Biolegend FC 
Anti-mouse-H2-Db KH95 Biotin Biolegend FC 
Anti-I-A/I- E M5/114.15.2 PB Biolegend FC 
Anti-IFN-γ XMG1.2 PE BD Pharmingen FC 
Purified rat anti–mouse CD16/32 
(mouse BD Fc block) 
- - BD Pharmingen FC 
H2-Kb-GP34-43 - PE Tcmetrix FC 
H2-Db-NP1396-404 - PE Tcmetrix FC 
H2-Db-NP1366-374 - PE Immudex FC 
CD80 blocking Ab 16-10A1 - Biolegend FC 
Mouse anti-human w6/32 - FITC Biolegend FC/IF 
Anti-mouse H2-Kb AF6-88.5 Biotin Biolegend FC/IF 
Anti-mouse-H2 M1/42 PE Biolegend FC/IF 
Anti-mouse CD28 - - BD Pharmingen ICS 
Anti-mouse CD3 - - BD Pharmingen ICS 
Rabbit anti-Rab11 - - Invitrogen IF 
SIGLEC-F E50-2440 Alexa 647 BD Bioscience IF 
Rabbit anti-mouse H2-Kb  Exon-8 - 
A gift from Dr. Jack Bennink, 
Bethesda, MD 
IP/WB 
Rabbit anti-LC3 PM036   MBL IP/WB/IF 
Mouse anti ATG5  7C6 - Nanotools, Teningen, Germany WB 
Anti-β-actin AC-15 HRP  Abcam WB 
Rabbit anti-RALBP1 - - EMELCA WB 
Rabbit anti-AAK1      Abcam WB/IF 
Rat anti-EBNA1 IH4 - 
Kindly provided by Dr. 
Friedrich Graesser 
(Uniklinikum Saarland) 
WB 
Table 5.1a List of primary antibodies 
FC, Flow Cytometry; IF, ImmunoFluorescence; ICS, IntraCellular Staining; IP, ImmunoPrecipitation; WB, western 
Blot. 
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Antibody Clone Conjugation Company Assay 
Streptavidin - PE Biolegend FC 
Goat anti mouse - Alexa555 Invitrogen IF 
Donkey anti rabbit Ig - Alexa 647 Invitrogen IF 
Goat anti rabbit Ig - Alexa 555 Invitrogen IF 
Goat anti mouse Ig - Alexa 647 Invitrogen IF 
Normal rabbit anti serum, Jackson  - - Jackson IP 
Goat anti rat - HRP Jackson Lab, Maine USA WB 
Goat anti rabbit - HRP Jackson Lab, Maine USA WB 
Goat anti mouse - HRP Biorad Lab, Hercules, CA, USA WB 
AffiniPure Goat Anti-Rabbit IgG (H+L)    HRP Jackson WB 
Table 5.1b List of secondary antibodies  
FC, Flow Cytometry; IF, ImmunoFluorescence; ICS, IntraCellular Staining; IP, ImmunoPrecipitation; WB, western 
Blot. 
5.2 Cell Lines and Cell Culture 
All suspension lymphoblastoid cell lines (LCLs) (721.45 T1 cells and CEMx174 T2 cells) were 
routinely cultivated in RPMI 1640 medium (Gibco) supplemented with 10% heat inactivated fetal 
calf serum (FCS) (R10) and 50 U/ml Penicillin/Streptomycin (Gibco). Cells expressing HLA-
B*3501, T2.B35 (generous gift from Prof. Rajiv Khanna, QIMR Berghofer Medical Research 
Institute, Brisbane, Australia) and T1.B35 cells, generated for this project by lentiviral infection, 
were additionally grown in selection R10 containing Geneticin, G418 (Thermo Fisher) (500 µg/ml).  
Adherent wild-type MEFs, used at maximum 25 passages, and human embryonic kidney (HEK) 
293T cells, which constitutively express the simian virus 40 (SV40) large T antigen, were cultured 
in Dulbecco's Modified Eagle Medium High Glucose medium (Gibco) with 10% FCS.  
Primary cells, bone marrow-derived DCs (BM-DCs) were cultured in RPMI-1640 supplemented 
with 50 U/ml penicillin/streptomycin, 20 ng/ml GM-CSF and 20% heat inactivated FCS. 
All cells were kept at 37°C and 5% CO2, in a humidified incubator and routinely checked for 
Mycoplasma following MycoScope™ PCR Mycoplasma Detection Kit (Genlantis).  
5.2.1 Expression constructs 
HLA-B*3501 has been cloned in frame with a sequence coding for green fluorescent protein 
(GFP; pEGFP-N1; CLONTECH Laboratories,Inc.) in the laboratory of Prof. Rajiv Khanna, QIMR 
Berghofer Medical Research Institute, Brisbane, Australia and kindly shared with us. This vector 
expresses HLA-B*3501 and GFP as fusion protein and contains resistance for Geneticin.  
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Three different modified EBNA1 (E1) construct were used. E1Δ, in which the GAr domain was 
deleted (Tellam, Sherritt et al. 2001); E1Δ-LC3 and Ii-E1Δ, in which the cDNA sequence of human 
LC3 or invariant chain (Ii) (Schmid, Pypaert et al. 2007; Leung, Haigh et al. 2010) were cloned 
upstream and in frame of the E1Δ gene. All constructs were cloned in pHR‐SIN‐CSGWDNotI 
(pCSGW) backbone with IRES‐GFP‐tag. 
5.2.2 Lentiviral production 
To produce lentivirus carrying the HLA-B*3501, GFP-E1Δ, GFP-E1Δ-LC3, and Ii-E1Δ constructs, 
HEK 293T cells were used. Cells were transfected with the plasmid of interest and two lentiviral 
packaging plasmids (pCMVΔR8.91 and pMDG) using a CaCl2 and 2X Hepes mix. Cells were 
incubated at 37°C for about 20 hours and then the medium was changed. About 30‐32 hours after, 
the viral supernatant was collected, centrifuged at 3000 rpm for 8 min at 8°C and then filtered 
through a 0.22 µm filter. The harvested virus was aliquoted and store at -80°C. 
5.2.3 Lentiviral Transduction 
LCLs were resuspended at a concentration of 5x106 cells/ml in the lentivirus supernatant and 
spin infected at 800 g for 1 hour. After centrifugation, cells were plated in 12 well plate over night 
at 2.5x106 cells/ml. Next day, cells were centrifuged and suspended in fresh R10. Five days after 
infection, the antibiotic G418 was added to select HLA-B*3501-positive cells. For E1Δ constructs, 
cells were FACS sorted for GFP on a FACS Aria Cell Sorter II (BD Biosciences). 
5.2.4 AAK1 silencing 
Stealth siRNA Primer Set Aak1 Mouse (Life Technology), referred to as C10 
(UCUACCCAGUGUUUCCCAACCUAAA), C12 (CAGAAGGCUCCACAUGGAAUCCUUU), and D02 
(CAGAGAAUGAAGUGCUGCGCAGAUAUU) were used to silence AAK1 expression in MEFs and Atg5-
/- and Atg5+/+ BM-DCs. Stealth siRNA at a concentration of 20 nM were introduced into 2x105 MEFS 
by oligofectamine (Life Technology) transfection in 6-well plate, following manufacturer’s 
instructions. After overnight incubation in serum-free medium, FCS was added at final 
concentration of 10%. Total incubation time for transfection was 96 hours in R10. BM-DCs were 
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silenced by electroporation using Neon transfection system (Thermo Fisher) with 200 pmol of 
siRNA for 2-3x106 cells. Cells were kept for 48 hours in GM-CSF supplemented R10. After AAK1-
targeting siRNA transfection, cells were harvested and analysed by western blot to assess AAK1 
expression levels and by FACS to evaluate changes on MHC-I levels at the surface.  
5.2.5 Generation of CD8+T cell clones 
EBNA1407-417-specific CD8+ T cell clones were generated from EBV-specific T cells sorted from 
the blood of a healthy HLA-B*3501 positive EBV carrier as previously described by Antisiferova 
and colleagues (Antsiferova, Muller et al. 2014). 
5.3 Animals and cell isolation 
Eights to 12 weeks old C57BL/6 mice (female and male) were purchased from Janvier Labs. 
Atg5fl/fl mice backcrossed for more than 9 generations on the C57BL/6 background (Hara, 
Nakamura et al. 2006), were a kind gift of Dr. Mizushima (University of Tokyo, Japan). Atg7fl/fl mice 
(Komatsu, Waguri et al. 2005) were kindly provided by Dr. Komatsu (Tokyo Metropolitan Institute 
of Medical Science, Japan). CD11c-Cre transgenic mice were from Jackson Laboratories. In these 
mice, the expression of a pIRES2-EGFP-based plasmid in CD11c positive cells is under control of 
the CD11c (Itgax) promoter and enhancer. Breeding CD11c-cre transgenic mice with any mouse 
containing a loxP-flanked sequence of interest, results in the constitutive Cre-mediated 
recombination of the flanked sequence in the offspring in tissues where the Itgax promoter is 
active. Accordingly, Atg5fl/fl or Atg7fl/fl mice were crossed to CD11c-Cre transgenic mice to obtain 
CD11c-cre x Atg5fl/fl or Atg7fl/fl (Atg5−/− or -Atg7-/- DCs, respectively) and Cre negative x Atg5fl/fl or 
Atg7fl/fl (Atg5+/+ or Atg7+/+ DCs, respectively) on a C57BL/6 background.  
All animals were bred and housed in the University of Zurich animal facility according to 
institutional guidelines and Swiss animal laws. All animal protocols were approved by and 
conducted in accordance with the cantonal veterinary office of the canton of Zurich, Switzerland 
(protocol nos. 117/2008, 134/2011, Medecine FRM 1005 and ZH210/2014).  
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5.3.1 Mouse organ collection 
Mice were euthanized by CO2 inhalation. Depending on the organ of interest, different leukocyte 
isolation protocols were applied. 
5.3.2 Isolation of splenocytes 
Fresh spleens were collected from Atg5-/- DC mice and their littermates, either infected or not 
with influenza virus and enzymatically digested with 200 μg/ml Collagenase D, 50 μg/ml DNase I, 
25 mM Hepes in R10 and incubate for 30 min at 37°C on shaker. To stop the reaction, 10 mM EDTA 
was added. Digested spleens were then smashed through the 70 μm strainer using piston of 2.5/5 
ml syringe, and washed with cold PBS. After centrifugation, erythrocytes were lysed by incubating 
samples with 1 ml ACK for Erythrocyte lysis (0.15 M NH4Cl, 1 mM KHCO3, and 0.1 mM EDTA, pH 7.2) 
for 3 min at room temperature. After wash, cells were resuspended in PBS and counted. For a 
detailed description see Loi et al. 2017(Loi, et al. submitted). 
5.3.3 Isolation of CD45-positive cells from the lung 
After perfusion with 10 ml PBS, lungs from either influenza A infected or not infected Atg5 and 
Atg7 sufficient and deficient mice were collected, cut into small pieces and digested with 400 
μg/ml Collagenase A, 50 μg/ml DNase I, 25 mM Hepes in R10 and incubate for 45 min at 37°C on 
shaker. Ten mM EDTA was added the last 5 min to stop the reaction. The tissue was then forced 
through a 40 μm strainer using piston of 2,5/5 ml syringe. Cells were washed with cold PBS and 
the CD45 positive fraction was isolated by Percoll. Cells were resuspend in PBS and counted. For a 
detailed description see Loi et al. 2017 (Loi, et al. submitted). 
5.3.4 Isolation of CD11c-positive cells  
Splenic and lung CD11c+ cells were isolated by positive magnetic cell separation (MACS) 
(Miltenyi Biotec) by resuspending the cells at a concentration of 2.5 x 108 cells/ml with cold MACS 
buffer (0.5% BSA, 2mM EDTA in PBS) and incubating with 100 μL CD11c beads (Miltenyi Biotec) 
per 108 cells at 4°C for 20 min. After wash in cold MACS Buffer, cells were resuspended 2 x 10 8 
cells/ml in cold MACS buffer and magnetic separation in the autoMACS separator (Miltenyi Biotec) 
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was performed by positive selection. MACS sorted CD11c+ cells, with a purity of 72-80% were then 
cultured in R10 supplemented with 20 ng/ml GM-CSF. Where indicated, CD11c+ MHC class IIhigh 
cells were sorted on a FACS Aria Cell Sorter II (BD Biosciences).  For a detailed description see Loi 
et al. 2017 (Loi, et al. submitted). 
5.3.5 Bone marrow derived DCs 
Bone marrow‐derived DCs (BM‐DCs) were obtained from femur and tibia of Atg5 and Atg7 
sufficient and deficient mice, flushed out with cold PBS, strained through a 70 µm cell strainer, 
centrifuged and then erythrocytes were lysed by ACK lysis for 5 min at room temperature. After 
PBS wash, cells were resuspended in pre-warmed BM‐DC medium and plated out at 3-5 x 106/ml in 
100 x 15 mm non-tissue coated petri dish in BM-DC medium and incubated at 37°C. The medium 
was changed every second day by collecting the cells in suspension, centrifugation at 500 g for 10 
min at 4°C and resuspending in new BM‐DC medium. Cells were plated back in the original plate. 
After 8/10 days of incubation BM‐DCs were used. BM-DCs purity was checked by FACS analysis 
and if necessary (<80% CD11c+ MHC class IIhigh cells) cells were enriched by MACS positive CD11c 
selection. For a detailed description see Loi et al. 2017 (Loi, et al. submitted). 
5.3.6 Flow cytometry 
Cells were acquired on a FACS Fortessa flow cytometer using FACS Diva Version 6.1.3 software 
(BD Biosciences) or a FACS Canto II (BD Biosciences) and all flow cytometry analyses were 
performed with FlowJo Version 9.3.1 software (Treestar). 
5.4 Biochemical Assays 
5.4.1 Lysate Preparation and Co-Immunoprecipitation  
Lysate preparation and co-immunoprecipitation (co-IP) was performed as described in Loi et al. 
2017 (Loi, et al. submitted). Briefly, cell protein extracts were obtained after PBS wash and either 
stored at -80°C or immediately resuspended in ice-cold lysis buffer (50 mM Tris pH 8.0, 140 mM 
NaCl, 1.5 mM MgCl2, 1% NP40) or in co-IP Lysis Buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% 
NP-40) for Western blot and co-IP, respectively, freshly supplemented with complete Proteinase 
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Inhibitor cocktail (Roche) and incubated for 30 min on ice (1 x 106 cells/ 50 µl). Cells and debris 
were centrifuged and protein amount was quantified using Pierce BCA Protein Assay Kit (Pierce) 
accordingly to the manufacturer’s recommendation. 
For IP, cell lysate were precleared with 50 µl of protein A beads (Pierce) and then equal amount 
of protein was incubated with 5µl of rabbit-anti Atg8/LC3 or 5µl of anti-H2-Kb (Exon8) (See Table 
5.1a) overnight on constant rotation. The next day, cell lysate was incubated with protein A beads, 
and after 1 hour extensively wash with PBS. 
Total protein extracts and IP fraction were boiled for 5 min in the presence of Sodium Dodecyl 
Sulphate (SDS)- PolyAcrylamide Gel Electrophoresis (PAGE) loading buffer (60 mM Tris-Cl, pH 6.8, 
2% SDS, 10% Glycerol, 0.01% Bromophenol Blue) with 1% β-mercaptoethanol. Western blot 
lysates were loaded onto a SDS-PAGE gel, while IP lysates were analysed by Western blot and/or 
mass spectrometry. 
5.4.2 Western blotting (WB) 
Western blotting was performed as described in Loi et al. 2017 (Loi, et al. submitted). Briefly, 
protein extracts were resolved in 7% or 12.5% SDS-PAGE gels 1.5mm thick. Primary antibodies 
(rabbit anti- LC3 1:1.000, rabbit anti-AAK1 1:1000, rabbit anti-RALBP1 1:1000, rat anti-EBNA1 
(See Table 5.1a) in 5% milk PBS containing 0.1% Tween 20 (Sigma) (PBS-T)) were incubated 
overnight at 4°C. After extensively washes with PBST, cells were incubated with appropriate HRP -
coupled secondary antibody (goat anti-rabbit Ig 1:50.000, goat anti-rat Ig 1:10.000 in PBS-T) for 1 
hour at room temperature. Anti actin-conjugated HRP antibody (1:100.000) was incubated on 
membrane for 30 min at room temperature as loading control. Protein bands were detected by 
application of ECL western blot substrate (Witec) and visualized with Fusion FX Detector (Vilber-
Lourmat). Quantification of protein levels by densitometry was performed using the Image J 
software. 
5.4.3 Mass Spectrometry (MS) 
Samples obtained from co-IP were reduced with 1 mM Dithiothreitol (Sigma‐Aldrich) and 
alkylated using 5.5 mM iodoacetamide (Sigma‐Aldrich). Proteins were separated by SDS -PAGE and 
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digested in gel using trypsin (Promega) at 37°C overnight and the resulting peptide mixtures were 
processed on STAGE tips. Mass spectrometric measurements were performed on a LTQ Orbitrap 
XL mass spectrometer (Thermo Fisher Scientific) coupled to an Agilent 1200 nanoflow‐high-
performance liquid chromatography (HPLC) (Agilent Technologies GmbH). The mass spectrometer 
was operated in the data‐dependent mode and switched automatically between MS (max. of 1 x10 6 
ions) and MS/MS. Each MS scan was followed by a maximum of five MS/MS scans in the linear ion 
trap using normalized collision energy of 35% and a target value of 5,000. Parent ions with a 
charge state from z = 1 and unassigned charge states were excluded for fragmentation. The mass 
range for MS was m/z = 370 to 2,000. The resolution was set to 60,000. Mass‐spectrometric 
parameters were as follows: spray voltage 2.3 kV; no sheath and auxiliary gas flow; ion‐transfer 
tube temperature 125°C. The MS raw data files were uploaded into the MaxQuant software (PMID 
(PMID): 19029910) version 1.3.0.5, which performs peak detection, quantification, and generates 
peak lists of mass error corrected peptides using the following parameters: 
carbamidomethylcysteine was set as fixed modification, methionine oxidation and protein amino-
terminal acetylation were set as variable modifications. Three miss cleavages were allowed, 
enzyme specificity was trypsin/P, and the MS/MS tolerance was set to 0.5 Da. Peak lists were 
searched by Andromeda for peptide identification using a Uniprot mouse database containing 
common contaminants such as keratins and enzymes used for in-gel digestion. Peptide lists were 
further used by MaxQuant to identify and relatively quantify proteins using the following 
parameters: peptide, and protein false discovery rates were set to 0.01, maximum peptide 
posterior error probability (PEP) was set to 1, minimum peptide length was set to 7, the PEP was 
based on Andromeda score, minimum number peptides for identification and quantitation of 
proteins was set to one and must be unique, and identified proteins have been re-quantified. 
5.5 MHC class I assays 
5.5.1 Internalization assay  
CD11c+ MACS sorted DCs were stained in FACS buffer (PBS supplemented with 2% FCS and 
0.01% Na azide) with either anti-H2-Db or anti-H2-Kb biotinylated antibodies, or their respective 
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isotypes, 1:50 for 30 min at 4°C. Cells were washed 2 times in PBS, resuspended in R10, and kept at 
4°C or incubated at 37°C, for 10, 30, 60 and 90 min. After the incubation time, cells were washed 
and surface staining was performed at 4°C with 1:400 PE-coupled streptavidin, 1:400 PE-Cy7-anti-
CD11c, 1:400 PB-anti-MHC-II, and 1:500 Aqua in FACS buffer. The rate of internalization of MHC-I 
molecules was evaluated by the decrease of MFI intensity compared to the MFI of control DCs 
incubated at 4°C and set as a reference at 100%. For a detailed description see Loi et al. 2017 (Loi, 
et al. submitted). 
5.5.2 Acid stripping assay 
CD11c+ MACS sorted DCs were incubated for 2 min with ice cold acid stripping buffer (131 mM 
sodium citrate, 66 mM sodium phosphate and 1% BSA, pH 3) then washed 2 times in R10, and kept 
at 4°C or incubated in R10 at 37°C for the indicated time points. After the incubation time, cells 
were washed and surface staining was performed at 4°C with anti-H2-Db or anti-H2-Kb, anti-CD11c, 
anti-MHC-II, and Aqua. Isotype staining was used as control. The rate of restoration of MHC-I 
molecules at the surface was evaluated by the increase of MFI intensity compared to the MFI of 
control DCs incubated at 4°C and set as a reference at 0%.  
5.6 Imaging Techniques 
5.6.1 Immunofluorescence of CD11c+ cells 
CD11-c positive cells were cultured overnight on Poly-L-Lysine coated glass slides (Menzel-
Gläser; 1.5mm) at 37°C in R10. The next day, cells were centrifuged 1500 rpm 3 min, washed in 
PBS and labelled with Fc blocker 2.4G2 Fcc III/II (BD PharMingen) at 4°C, followed by labelling for 
H2-Kb or H2 (see Table 5.1a) for 30 min at 4°C in PBS. Next, they were incubated at 37°C for 1 h, 
washed with PBS and fixed in 4% paraformaldehyde 20 min at room temperature. After fixation, 
cells were washed with PBS, permeabilized with 0.1% Triton X100 for 5 min room temperature, 
wash with PBS and saturated with 1% BSA for 1 hour. Binding of the primary antibody was 
detected with Alexa Fluor 555 goat anti-mouse or anti-rat IgG H&L (Invitrogen) and cell nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI). Fluorescence was analysed with a 63×, 
1.4 NA oil immersion lens with a confocal laser-scanning microscope (SP8; Leica). Analyses have 
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been performed using ImageJ software. For a detailed description see Loi et al. 2017 (Loi, et al. 
submitted). 
5.6.2 Immunofluorescence of LCLs 
LCLs cells were seeded on Poly-D-Lysine coated round glass coverslips in a 24 well plate and 
fixed in 4% PFA 20 min after centrifugation (800 g, 5 min). All steps were performed at room 
temperature and all washes done with PBS supplemented with 1% BSA (Sigma). Cells were 
permeabilized with 0.5% Saponin 1%BSA in PBS for 5 min, washed 3 times 10 min followed by 
staining with primary antibodies mouse anti-human w6/32, rabbit anti-LC3, rabbit anti-RAB11, 
guinea pig anti-p62 (See Table 5.1a) for 1 hour. Suitable secondary antibodies conjugated with 
either Alexa Fluor 488 or Alexa Fluor 555 were incubated for 30 min. Slides were counterstained 
with DAPI (Invitrogen) and mounted with Fluorescence mounting medium (Dako). Cells were 
visualized through a 63×, 1.4 NA oil immersion lens with a confocal laser-scanning microscope 
(SP8; Leica). Colocalization analyses have been performed using the Coloc2 Plugin of ImageJ 
software. A Pearson coefficient >0.5 indicates a statistically relevant colocalization of the signals.  
5.7 Enzyme-linked immunosorbent assay (ELISA) 
5.7.1 IFN-γ production of EBNA1-specific CD8+ T cell clone 
The EBNA1407-417-specific CD8+ T cell clones were incubated overnight with HLA-B*3501 T1 and 
T2 cells in an effector to target ratio of 1:10. IFN-γ released was quantified by ELISA. As positive 
controls were pulsed with 1µM peptide EBNA1407-417 prior coculture. 
5.7.2 Lung homogenate preparation 
For detection of cytokines in the lungs, lungs were weighted and resuspended in PBS (400 mg in 
1.5 ml), then disrupted mechanically, using a Polytron. Homogenates were then centrifuged at 
13,000 RPM for 30 min, and supernatants were tested for cytokine detection.  
5.7.3 IL-6, IL-1β, IFN-γ ELISAs 
Murine lung homogenates and human cell supernatants were added undiluted onto previously 
coated 96-well ELISA plates (Nunc-Immuno MaxiSorp; Thermo Fisher Scientific). Cytokines were 
Materials and Methods 
82 
 
then detected with the biotinylated specific antibodies (IL-6 eBioscience kit 88-7013-88; IL-1β 
BioLegend kit 431303; mouse IFN-γ eBioscience kit 88-7314-86; human IFN-γ Mabtech 3420-1H-
20) and streptavidin-HRP (Mabtech), using the peroxidase substrate tetramethylbenzidine (TMB, 
Sigma). Recombinant cytokines were used as standard. Plates were read using Microplate Reader 
Infinite M1000 Pro (Tecan) at 450 nm and 570 nm as reference value.  
5.7.4 Serum isolation 
Blood for serum cytokine analysis was collected via cardiac puncture after euthanasia with CO 2 
inhalation. After collection in Microtainer SST tubes (BD), the whole blood has been allowed to clot 
by leaving it at room temperature. After 15-30 min the clot was removed by centrifuging at 2000 g 
for 10 min at 4°C. Serum was aliquoted and stored at -80°C. 
5.7.5 Influenza specific IgG detection 
ELISA plates were coated with 100 µl/well PR8 Virus 1:1000 in PBS, and incubated o/n at 
4°C.the day after the virus were inactivated with 2x auto-linking modus (=240mjoules). After 
blocking with 200 µl/well blocking solution (1% BSA in PBS pH 7.4) for 2 hours at room 
temperature, 50 µl/well of serum of infected mice previously titrated 1/800 to 1/102400 in 0.1% 
BSA/PBS were incubated for 2hours at room temperature. Serum from PBS treated mice were used 
as control. Washes with PBS 0.05% Tween were followed by incubation with 50 µl/well goat anti-
mouse HRP antibody 1:500 in PBS/0.1% BSA and incubate for 1.5 hours at room temperature. TMB 
was used as peroxisade substrate and plates were read using Microplate Reader Infinite M1000 
Pro (Tecan) at 450 nm and 57 0nm as reference value.  
5.8 Molecular Assays 
5.8.1 DNA extraction from biopsies 
Tail or ear biopsies (0.3-0.6 cm) were obtained from mice were either stored at −20 °C or 
immediately immersed in 100 μl of tail lysis buffer  (100 mM Tris, pH 8.0, 100 mM NaCl, 10 mM, pH 
8.0, 0.2% SDS) freshly supplemented with 1:50 of proteinase K (Roche). Tissue biopsies were 
digested between 4-12 hours at 56 °C at 550 rpm, centrifuged to remove the tissue debris and 
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transferred to a collection tube containing 200 μl isopropanol. After centrifugation, supernatants 
were discarded and 200 μl of 70%-Ethanol was added. Tubes were centrifuged, supernatants 
discarded and let them dry. DNA was resuspended in 100 μl of ddH2O and stored at-20°C. 
5.8.2 Genotyping 
For Atg5fl/fl allele and Atg7fl/fl allele genotyping, respectively, the Taq DNA Polymerase (Roche, 
stock 5 U/µl) and the TaKaRa LA Taq® DNA Polymerase (Clontech) were used. Cre allele was 
genotyped with the FIREPol® 5× Mix 7.5 mM Ready to Load system (SOLIS BIODYNE).  
A PCR master mix was prepared in water accordingly to the different protocol. Water and a 
negative mouse sample were used as negative control, a positive mouse sample served as positive 
control. For primers used see Table 5.2; Master mix for PCR Table 5.3. The PCR was run according 
to Table 5.4. DNA bands were resolved in 1% agarose gel in tris‐borate‐EDTA buffer 
supplemented with GelRed to stain the DNA. Samples were analyzed with the AlphaImagerTM 
2200. 
5.8.3 qRT-PCR 
Atg5+/+ and Atg5-/- lung DCs were FACS sorted for CD11c, MHC-II, SIGLEC-F, CD103 and CD11b 
while splenic DCs for CD11c, MHC-II, CD8 and CD11b. mRNA was extracted with Quick-RNA 
MicroPrep kit (Zymo Research) following the manufacturer instructions. Briefly, after adding 300 
μl of RNA lysis buffer, samples were stored at -80°C as recommended by the manufacturer’s 
instructions. The day after, 1 volume of ethanol was added and after mixing samples were transfered 
into a Zymo-Spin IC Column and briefly centrifuge. DNase treatment was performed in-column 
followed by RNA Prep Buffer and washing steps. RNA was eluted with DNase/RNase- free H2O and 
either used immediately or store at -80°C. 
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Primer name   Primer Target Primer sequence (5’- 3’) 
Genotyping   
CS003 Atg5fl/fl   GAATATGAAGGCACACCCCTGAAATG 
CS004 Atg5 fl/fl  GTACTGCATAATGGTTTAACTCTTGC 
CS005 Atg5 fl/fl ACAACGTCGAGCACAGCTGCGCAAGG 
CS006 Atg5 fl/fl CAGGGAATGGTGTCTCCCAC 
CS014 Atg7 fl/fl TGGCTGCTACTTCTGCAATGATGT 
CS015 Atg7 fl/fl CAGGACAGAGACCCATCAGCTCCAC 
CS007 CD11c-Cre-GFP GCGGTCTGGCAGTAAAAACTATC 
CS008 CD11c-Cre-GFP  GTGAAACAGCATTGCTGTCACTT 
CS009 CD11c-Cre-GFP (+ve ctr) CTAGGCCACAGAATTGAAAGATCT 
CS010 CD11c-Cre-GFP (+ve ctr) GTAGGTGGAAATTCTAGCATCATCC 
Virology   
GAPDH-Forward CCTGGAGAAACCTGCCAAGTA 
GAPDH-Reverse AGAGTGGGAGTTGCTGTTGAA 
PR8 NA-Forward TTGGTCAGCAAGTGCATGTC 
PR8 NA-Reverse ACAGCCACTGCTCCATTATC 
PR8 M-Forward CAAGCAGCAGAGGCCATGGA 
PR8 M-Reverse GACCAGCACTGGAGCTAGGA 
PR8 HA-Forward CTGCTCGAAGACAGCCACAA 
PR8 HA-Reverse GAGCCATCCGGCGATGTTAC 
Table 5.2 List of primers 
For the RNAcDNA reverse transcription, 1 μl Random Hexamer Primers (Promega) was added 
to 9.5 μl of RNA (max 5 μg), and placed for 5 min into a heat-block at 70°C. After centrifugation, 9.5 
μl of the reaction mix (Promega) was added and the amplifying program was set as in Table 5.5. 
cDNA was stored at -20°C or used immediately for qRT-PCR used to quantify H2-Kb mRNA 
levels. qPCR reaction was set as in Table 5.6 in 384 well plate. For each sample duplicates of 
triplicates were performed. 1 μl of DNase/RNase free H2O was used as negative control. 
Additionally, GAPDH mRNA quantification was used as reference gene. qRT-PCR was run as in 
Table 5.6.  
Cq values were determined using the regression method. Briefly, average Ct (threshold cycle) 
value was calculated for all samples and GAPDH average Ct values were subtracted from the 
average Ct values of the H2-Kb obtaining the ΔCt. Normalized gene of interest expression levels 
were calculated as 2ΔCt. 
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Reagent 
Atg5 Master Mix Atg7 Master Mix Cre Master Mix 
Volume Concentration Volume Concentration Volume Concentration 
DNA 5 μl   5 μl   2 μl   
PCR buffer 5 μl 10x buffer 2 μl 10x Takara buff 4 μl 5x FIREPol 
dNTPs 1 μl 10 mM 3.2 μl 2.5 mM 0 μl   
primers 1 μl 10 μM 0.2 μl 20 μM 0.5 μl 10 μM 
Taq Polymerase 0.4 μl   0.2 μl   0 μl   
H2O 34.6 μl   12.2 μl   12 μl   
Final Volume 50 μl   20 μl   20 μl   
Table 5.3 Recipes Master Mix for genotyping 
Atg5  Atg7  Cre  
Temperature Time Temperature Time Temperature Time 
95°C 3 min   94°C 5 min   94°C 4 min   
95°C 30 sec   94°C 30 sec   94°C 30 sec   
60°C 30 sec  X 35 65°C 30 sec X 30 63°C 45 sec X 35 
72°C 1 min   68°C 90 sec   72°C 1 min   
72°C 10 min   72°C 10 min   72°C 10 min   
4°C ∞ 
 
4°C ∞ 
 
4°C ∞ 
 
Table 5.4 PCR programs for genotyping 
Reagent 
Master Mix 
 
PCR Retrotranscription 
Volume Concentration 
 
Temperature Time 
PCR buffer 4 μl 5x buffer 
 
25°C 5 min   
MgCl2 1 μl 3.8 mM 
 
42°C 60 min   
dNTPs 1 μl 10 mM 
 
70°C 15 min   
RNase Inhibitor 0.5 μl 10 μM 
 
4°C ∞ 
 
Retrotranscriptase 1 μl   
    DNase/RNase free H2O 2 μl   
    Final Volume 9.5 μl   
    
Table 5.5 Master mix (left) and PCR programs (right) for retrotranscription 
Reagent 
Master Mix 
 
qRT-PCR 
Volume Concentration 
 
Temperature Time 
cDNA 1μl   
 
50°C 2 min   
SYBR Green SuperMix 5 μl   
 
95°C 2 min   
Primers 0.4 μl 10 μM 
 
95°C 15 sec X 30 
DNase/RNase free H2O 3.6 μl   
 
60°C 1 min   
Final Volume 10 μl   
 
4°C ∞ 
 
Table 5.6 Master mix (left) and PCR programs (right) for qRT-PCR program 
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5.9 Virology 
5.9.1 Influenza virus infection in vitro and in vivo 
CD11c+ MACS sorted splenic DCs were infected at a MOI of 200 for 45 min in RPMI without 
serum. Influenza A/PR8 virus (H1N1) virus was used for all experiments and purchased from 
Charles River. Mice were anesthetized using isoflurane and infected intranasally by the application 
of 25 µl of virus suspension (doses of virus were chosen between 0.1 to 10 HA units depending on 
the experiment). Weight loss was used to follow the development of the infection.  
5.9.2 LCMV infection in vivo 
Animals were infected intravenously with the wild type LCMV Armstrong strain at a dose of 10 4 
PFU. 
5.9.3 Quantification of viral RNA 
Lungs were weighted and resuspended in PBS (400 mg in 1.5 ml). Briefly, lungs were disrupted 
mechanically using a Polytron and viral RNA was isolated according to the manufacturer’s 
instructions (Qiagen viral RNA isolation kit). Reverse transcription was performed using the 
GoScript reverse transcription system (Promega). The RT product was diluted and used as a 
template for quantitative PCR (qPCR) on a Bio-Rad MyIQ detection system using the Platinum 
SYBR Green qPCR SuperMIx-UDG (Invitrogen). The specific forward (F) and reverse (R) primer 
pairs (all Eurofins MWG, Ebersberg, Germany) were used. Relative concentrations of viral RNA in 
the cells was determined by analysis of cycle threshold values (Ct), normalizing the mean Ct for 
PR8-M, PR8-HA and PR8-NA to the expression of the product of the housekeeping gene GAPDH 
obtaining the ΔCt. ΔCt of PBS treated mice was subtracted for the ΔCt obtained from 
influenza infected mice and the normalized gene of interest expression levels were 
calculated as 2ΔΔCt. 
5.9.4 Influenza infectious titre plaque assay 
Virus titration was performed by plaque assay. MDCK cells were seeded in 12-well tissue 
culture plates in high-glucose Dulbecco's modified Eagle's medium (DMEM) with 10% heat-
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inactivated FCS and 1% penicillin–streptomycin. Serial 10-fold dilution of the samples (0.1 ml) 
were prepared in infection buffer (0.3% BSA, 1% penicillin–streptomycin, 0.02 mM Ca2+and 
0.01Mg2+in PBS) and added onto the MDCK cell monolayer for 1 h at 37°C with intermittent 
shaking. Each dilution was plated in triplicates. After incubation, the inoculum was taken off and 
1ml of agar overlay (2x MEM, 0.02% DEAE-Dextran, 0.15% Sodiumcarbonate and 0.04% Oxoid 
agar) supplemented with 0.5 µg/ml of tosyl phenylalanyl chloromethyl ketone (TPCK)-trypsin was 
added to each inoculated well. Solidified agar plates were incubated at 37°C for 1.5 days. Plates 
were then fixed with 4% paraformaldehyde for 20 min and, after removal of the agar layer, crystal 
violet solution (40ml of 1% crystal violet, 80ml methanol in H2O) was added for 10 min. Plates 
were rinsed with tap water and plaques were counted to determine the viral titer as plaque-
forming units (PFU) per ml. 
5.9.5 Influenza virus specific T cell proliferation 
Influenza specific polyclonal T cells were expanded from splenocytes or lung of C57BL/6 mice 
at day 12/14 post-influenza infection, as previously described (Longhi, Trumpfheller et al. 2009). 
Briefly, C57BL/6 mice were intranasally infected with 10 HAU of PR8 virus. After 12/14 days were 
sacrificed and organs collected and processed as described in Isolation of mouse cells section. One 
third of the cells 5x106 cells/ml was then infected with PR8 in vitro at a MOI of 10 in plain RPMI at 
37°C. After 1 hour, cells were washed, resuspend at 2.5x106/ml and irradiate at 30 Grays. Irradiate 
and not irradiate cells were plate in 24-well plate at 2.5x106/ml and cultured for 6/7 days in RPMI 
supplemented with 10% FCS, and 40 units/ml of IL-2.  
For DC/T cell co-cultures, Atg5+/+ and Atg5-/- CD11c+ splenic or lung DCs were influenza infected 
in vitro at a MOI of 200 and seeded overnight in R5 supplemented with GM-CSF or pulsed with 0.1 
or 1 µM NP1366-374 peptide for 1 hour. CD11c+ DCs were then co-cultured in 96 flat bottom plates, at 
a 1/1 ratio with CFSE labelled IAV specific T cells obtained from spleen or lungs of C57BL/6 
infected animals as described above for 3/4 days. Proliferation of CD8 +T cells was evaluated by 
FACS staining. Co-culture with non-infected DCs was used as a control. In some experiments, CD80 
specific blocking antibodies were added (10 µg/ml) during the DC co-culture with T cells. 
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5.9.6 Intracellular IFN-γ staining 
Lung single cell suspensions obtained after Percoll gradient centrifugation were incubated in 
RPMI at 37°C for 5 hours in the presence of anti-CD28 (2 µg/ml) and influenza specific peptides 
(10 µg/ml). Brefeldin A (10 µg/ml) (Sigma) was added after the first hour. As positive control anti-
CD3ε/anti-CD28 or phorbol myristate acetate (PMA)/Ionomycin (Sigma) was added. Extracellular 
staining was performed with the following mix: 1:500 PB anti-mouse CD4, 1:125 APC anti-mouse 
CD8, 1:50 APC-Cy7 anti-mouse CD45, 1:500 Aqua Live/Dead for 20 min on ice. Then cells were 
fixed and permeabilized using BD Cytofix Cytoperm Fixation/Permeabilization Kit, stained for PE-
anti-IFN-γ and analysed by FACS. For a detailed description see Loi et al. 2017  (Loi, et al. 
submitted). 
5.10 Statistical analysis 
Statistical tests applied are indicated in the respective figure legends and performed with 
GraphPad Prism v5.0a for Mac OSX (GraphPad Software, Inc). Unpaired, two-tailed student t test, 
Mann-Whitney U test and Pearson correlation coefficient were performed/calculated. A P-value 
<0.05 was considered statistically significant.  
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Abbreviation full name 
AAK1 Adaptor protein-Associated Kinase 
AMPK AMP-activated Protein Kinase 
AP Adaptor Protein 
APC AlloPhycoCyanin 
APC-Cy7 AlloPhycoCyanin-Cyanin7 
ATG Autophagy-related protein 
Atg Autophagy-related gene 
ATP Adenosine TriPhosphate 
Bcl-2 B-cell lymphoma 2 
BM-DC Bone Marrow-Derived DC 
BSA Bovine Serum Albumine 
CD Cluster of Differentiation 
CFSE CarboxyFluorescein Succinimidyl Ester 
CMA Chaperone-Mediated Autophagy 
CQ Chloroquine 
Cre Cyclization (or causes) recombination enzyme 
DAPI 4',6-DiAmidino-2-PhenylIndole 
DC Dendritic Cell 
DEC-205 Dendritic and Epithelial Cells, 205 kDa 
DNA DeoxyriboNucleic Acid 
DNase DeoxyriboNuclease 
dNTP deoxyNucleotide TriPhosphates 
DRiP Deferctive Ribosomal Product 
EBNA EBV Nuclear Antigen 
EBV Epstein Barr Virus 
EDTA Ethylenediaminetetraacetic acid 
EGFR Enhanced Green Fluorescent Protein 
ELISA enzyme-linked immunosorbent assay 
ER Endoplasmatic Recticulum 
ERC Endosomal Recycling Compartment 
ERGIC ER-Golgi Intermediate Compartment 
FLICE Fas-associated death domain-like interleukin-1β-converting enzyme 
Fl or flox DNA sequence that is flanked by two loxP sites 
GABARAP GABA Type A Receptor-Associated Protein 
GABARAPL GABA Type A Receptor-Associated Protein Like 
GAr Glycine Alanine Repeat 
GDP Guanosine DiPhosphate 
GFP Green Fluorescent Protein 
GM-CSF Granulocyte-Macrophage Colony-Stimulating Factor 
GP GlycoProtein 
GTP Guanosine TriPhosphate 
HA Haemagglutinin 
HAU hemagglutination Unit 
HLA Human leukocyte antigen 
HRP Horseradish peroxidase 
IAV Inflenza A Virus 
IFN Interferon 
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Abbreviation full name 
IL InterLeukin 
IRES Internal Ribosome Entry Site 
kb KiloBase 
kDa Kilo Dalton 
LAMP2 Lysosome-Associated Membrane Protein 2 
LAP LC3-associated phagocytosi 
LC3 Microtubule-associated protein 1A/1B-light chain 3 
LCL Lymphoblastoid cells  
LIR LC3-Associated Region 
LMCV LyMphocytic Choriomeningitis Virus  
LMP Latent Membrane Proteins  
MACS Magnetic Cell Separation 
MARCH Membrane-Associated RING-CH 
MEF Murine Embronic Fibroblast 
MFI Mean Fluorescence Intensity 
MHC Major Histocompatibility Complex  
MIIC MHC-II loading compartment 
min minute 
MS Mass Spectrometry 
mTOR mammalian Target Of Rapamycin  
MVB Multi Vesiculr Body 
NA Neuraminidase 
NK Natural Killer 
NADPH Nicotinamide adenine dinucleotide phosphate 
NP NucleoProtein 
PAGE PolyAcrylamide Gel Electrophoresis 
PB Pacific Blue 
PBS Phospate Buffer Saline 
PBS-T PBS 0.2% Tween20 
PCR Polimerase Chain Reaction 
PE phosphatidylethanolamine 
PE Phycoeritrin 
PE-Cy7 Phycoeritrin cyanin7 
PFU Plaque forming Unit 
qRT-PCR 
quantitative real-time reverse transcription polymerase chain 
reaction 
RPMI Roswell Park Memorial Institute 
R10 RPMI 10% FCS 
RALBP1 RalA Binding Protein 1  
RNA RiboNucleic Acid 
ROS Reactive-Oxygen Species  
SDS Sodium Dodecyl Sulphate 
SIGLEC Sialic Acid binding Ig-like lectin 
SNARE Soluble NSF Attachment Receptors 
SQSTM1/p62 Sequestrosome 
sec second 
Abbreviations 
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Abbreviation full name 
T1.B35 HLA-B*3501 trasfected 721.45 T1  
T2.B35 HLA-B*3501 trasfected CEMx174 T2  
TAP Transporter-Associated with antigen Presentation 
VAMP Vesicle-Associated Membrane Proteins 
VPS Vacuolar Protein Sorting 
β2m Beta2-microglobulin 
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